

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK

MARIANNE RAFTIS,

Plaintiff,

-against-

MERCK & CO., INC.,

Defendant.

No.: 1:08-cv-030675GBD

**DECLARATION OF
VILIA B. HAYES**

VILIA B. HAYES declares as follows:

1. I am an attorney admitted to practice before this Court and a member with the firm of Hughes Hubbard & Reed LLP, attorneys for defendant Merck & Co., Inc. ("Merck"). As such, I am fully familiar with the facts set forth herein. I make this declaration based on my own personal knowledge and the business records of the Firm.

2. I make this declaration in support of Defendant's Combined Reply Memorandum in Support of Motion to Stay, and in Opposition to Plaintiff's Motion to Remand.

3. Attached hereto as Exhibit A is a true and correct copy of the Memorandum and Order issued in *Aguilar v. Merck & Co., Inc.*, No. 05-CV-4865 (SJ) (E.D.N.Y. Nov. 22, 2005).

4. Attached hereto as Exhibit B is a true and correct copy of the transcript of the Status Conference held in *In re VIOXX Products Liability Litigation*, MDL No. 1657, before the Honorable Eldon E. Fallon on June 23, 2005.

5. Attached hereto as Exhibit C is a true and correct copy of the letter from the JPML to the Honorable Ricardo H. Hinojosa, dated March 21, 2005.


6. Attached hereto as Exhibit D is a true and correct copy of the March 6, 2008 Stipulation of Dismissal with Prejudice Against Pfizer Defendants.

7. Attached hereto as Exhibit E is a true and correct copy of Case Management Order 6 in *In re: New York Bextra and Celebrex Product Liability Litigation*, dated August 14, 2006.

8. Attached hereto as Exhibit F is a true and correct copy of the Plaintiff Profile Form submitted to Merck by Marianne Raftis, dated October 16, 2007.

9. Attached hereto as Exhibit G are true and correct copies of excerpts from Marianne Raftis' medical records as submitted by Marianne Raftis to Merck.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.



VILIA B. HAYES

Executed this
24th day of April, 2008

Exhibit A

Case 1:05-cv-04865-SJ-RLM Document 16 Filed 11/22/2005 Page 1 of 6

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF NEW YORK

EVERARDO S. AGUILAR,

Plaintiff,

MEMORANDUM AND ORDER

-against-

05-CV-4865 (SJ)

MERCK & CO., INC., et al.,

Defendants.
_____x

ROANNE L. MANN, UNITED STATES MAGISTRATE JUDGE:

Currently pending before this Court is an application by defendant Merck & Co., Inc. ("defendant" or "Merck") to stay this action pending a decision by the Judicial Panel on Multidistrict Litigation ("the MDL Panel") whether to transfer the case as a "tag-along" action to In re VIOXX Products Liability Litigation, MDL No. 1657, an MDL action pending in the Eastern District of Louisiana. Plaintiff Everardo S. Aguilar ("plaintiff" or "Aguilar") has consented to stay discovery only, has cross-moved to remand the case to state court and opposes any stay of that motion.

For the reasons that follow, defendant's motion to stay this action is granted in its entirety, and the motion to remand is deferred until the issue of transfer is resolved by the MDL Panel.

BACKGROUND

On September 21, 2005, plaintiff commenced this action in New York State Supreme Court, Queens County, against Merck (the manufacturer of the prescription drug Vioxx) and a series of medical providers who are alleged to have improperly prescribed Vioxx to plaintiff. Merck removed the action to this Court on October 17, 2005, on the basis of diversity

Case 1:05-cv-04865-SJ-RLM Document 16 Filed 11/22/2005 Page 2 of 6

jurisdiction, contending that the non-diverse medical providers were fraudulently joined in order to defeat diversity jurisdiction.

On October 31, 2005, Merck moved to stay all further proceedings in this district pending a decision by the MDL Panel on whether the case should be transferred to the MDL Court in the Eastern District of Louisiana pursuant to 28 U.S.C. § 1407.¹ On November 7, 2005, the MDL Panel issued its thirtieth conditional transfer order of tag-along cases, which, absent an objection within 15 days, would transfer this case and others to the MDL Court. See 11/15/05 Letter to the Court from Vilia B. Hayes and Conditional Transfer Order (CTO-30), appended thereto.² That same day, plaintiff moved in this district to remand the instant action to state court. See Memorandum of Law in Support of Plaintiff's Motion for an Order Remanding this Matter to State Court ("Pl. Mem."). Plaintiff resists having the remand motion deferred until after the MDL Panel has transferred the case. See id. at 5-7; Plaintiff's Partial Opposition to Merck's Motion for Stay.

DISCUSSION

As plaintiff correctly contends (see Pl. Mem. at 5), the pendency of a request to transfer a case to an MDL proceeding does not divest the transferor court of the authority to resolve a motion to remand the case to state court. See, e.g., JPML R. 1.5; Evans v. Merck & Co., Inc.,

¹ The MDL Panel established the MDL proceeding on February 16, 2005. See In re VIOXX Prods. Liab. Litig. (MDL 1657), 360 F.Supp.2d 1352 (J.P.M.L. Feb. 16, 2005). To date, more than 2,500 cases have been transferred to or filed directly in the MDL proceedings. See Memorandum of Law in Support of Motion of Defendant Merck & Co., Inc. to Stay All Proceedings Pending a Decision on Transfer by the Judicial Panel on Multidistrict Litigation at 3.

² This Court has no information as to whether plaintiff has filed with the MDL Panel an objection to transfer.

Case 1:05-cv-04865-SJ-RLM Document 16 Filed 11/22/2005 Page 3 of 6

No. 05-1323-T/AN, 2005 WL 3008643, at *1 (W.D. Tenn. Nov. 9, 2005). Even after the MDL Panel has issued a conditional transfer order, the transferor court retains the discretion to grant or deny a motion to stay consideration of a jurisdictional challenge. See id.; North v. Merck & Co., Inc., No. 05-CV-6475L, 2005 WL 2921638, at *1 (W.D.N.Y. Nov. 4, 2005). The jurisdiction of the transferor court does not end until the order of the MDL Panel transferring the case has been filed with the MDL Court. See David F. Herr, Annotated Manual for Complex Litigation § 20.131 (4th ed. 2004) (hereinafter "Manual for Complex Litigation").

In connection with the Vioxx litigation, the MDL Panel has expressly observed that "[t]he pendency of a motion to remand to state court is not a sufficient basis to avoid inclusion in Section 1407 proceedings." In re VIOXX Prods. Liab. Litig., 360 F.Supp.2d 1352, 1354 (J.P.M.L. Feb. 16, 2005). Indeed, in establishing the Vioxx MDL, the Panel transferred to the MDL Court two actions with pending motions to remand to state court. See id. at 1353-54. According to the MDL Panel, the motions to remand in those two cases, "as well as in any other MDL-1657 actions[,] can be presented to and decided by the transferee judge." Id. at 1354 (citing In re Ivy, 901 F.2d 7 (2d Cir. 1990)).

The Panel's decision is consistent with the law in the Second Circuit, where the "preferable practice" in MDL litigation is to allow the transferee court to resolve jurisdictional issues that implicate common questions of law and fact arising in numerous cases. Medical Soc'y v. Conn. Gen. Corp., 187 F.Supp.2d 89, 91 (S.D.N.Y. 2001) (citing Ivy, 901 F.2d 7); see, e.g., North, 2005 WL 2921638, at *1 (noting, in Vioxx case, that the Second Circuit has adopted the "general rule" of deferring decisions on remand motions until after the MDL Panel has transferred the case); DeBono v. American Home Prods. Corp., No. 04 Civ. 3810(DC), 2005 WL

Case 1:05-cv-04865-SJ-RLM Document 16 Filed 11/22/2005 Page 4 of 6

2601177, at *1 (S.D.N.Y. Nov. 16, 2004) (“[T]he Second Circuit has observed that an MDL Court is often best suited to resolve remand motions, especially when the issues involved are likely to recur.”). As the Second Circuit observed in Ivy, where the jurisdictional issue “is easily capable of arising in hundreds or even thousands of cases in district courts throughout the nation,” and “involves common questions of law and fact,” “[c]onsistency as well as economy is . . . served” by having the jurisdictional objections “heard and resolved by a single court . . .” Ivy, 901 F.2d at 9; see Manual for Complex Litigation § 20.131 (“[T]he pendency of motions raising questions common to related actions can itself be an additional justification for transfer.”).

The aforesaid general rule should be followed in the instant case. Merck has challenged the joinder of doctors and/or pharmacies in other Vioxx cases in this circuit, and the plaintiffs’ motions to remand have been deferred until after transfer to the MDL litigation, on the ground that “the issues raised in plaintiff’s remand motion are not unique to this case.” North, 2005 WL 2921638, at *2; Krieger v. Merck & Co., Inc., No. 05-CV-6338L, 2005 WL 2921640, at *2 (W.D.N.Y. Nov. 4, 2005); see also Evans, 2005 WL 3008643, at *1 (“[T]he jurisdictional issues raised in this case are similar to those raised in other [Vioxx] cases that have been or will be transferred to the MDL proceeding.”); Walker v. Merck & Co., Inc., No. 05-CV-360-DRH, 2005 WL 1565839, at * 2 (S.D. Ill. June 22, 2005) (“[I]t is almost certain that the transferee court will hear and decide many of the same issues Plaintiffs ask this Court to tackle in ruling on their motion to remand.”). To be sure, a number of Vioxx decisions from outside this circuit have

Case 1:05-cv-04865-SJ-RLM Document 16 Filed 11/22/2005 Page 5 of 6

resolved remand motions prior to the MDL Panel's decision on transfer.³ Nevertheless, "there are many more that have chosen to grant a stay," Evans, 2005 WL 3008643, at *1 (collecting cases), including the two decisions from within this circuit. North, 2005 WL 2921638; Krieger, 2005 WL 2921640, at *2 (granting stay and noting that courts around the country have stayed Vioxx cases "pending their transfer to the MDL, including more than 125 with pending remand motions."); see, e.g., West v. Merck & Co., Inc., No. 05-1166-T/AN, 2005 WL 1630034 (W.D. Tenn. July 7, 2005); Walker, 2005 WL 1564839. Moreover, at a proceeding in the Vioxx MDL litigation, Judge Eldon B. Fallon, the district judge presiding over the MDL proceeding, expressly acknowledged the advantages of having a single judge decide the many motions to remand, and he assured the parties that he would deal with the motions "as quickly as possible . . ." Transcript of 6/23/05 Status Conference in In re VIOXX Prods. Liab. Litig., at 21 (appended as Exhibit A to the Declaration of Vilia B. Hayes dated 11/22/05 ["Hayes Decl"])).

Having considered these decisions and the parties' arguments, this Court concludes "that having the jurisdictional issues decided in one proceeding will promote judicial economy and conserve judicial resources," Evans, 2005 WL 3008643, at *2, and will minimize "the risk of inconsistent rulings . . ." North, 2005 WL 2921638, at *2 n.2 (quoting Purcell v. Merck & Co., No. 05 CV 0443-L(BLM), slip. op. at 4-5 (S.D. Cal. June 6, 2005) (Hayes Decl. Ex. B)); see North, 2005 WL 2921638, at *2 ("I agree with Merck that the objectives of the MDL process—namely the avoidance of inconsistent rulings and the conservation of judicial resources—are best

³ See, e.g., Plubell v. Merck & Co., Inc., No. 05-0831-CV-W-HFS, 2005 WL 2739036 (W.D. Mo. Oct. 20, 2005); Rabe v. Merck & Co., Inc., Nos. Civ. 05-363-GPM, 05-378-GPM, 2005 WL 2094741 (S.D. Ill. Aug. 25, 2005); Kantner v. Merck & Co., Inc., No. 1:04CV2044-JDT-TAB, 2005 WL 277688, at *3 (S.D. Ind. Jan. 26, 2005).

Case 1:05-cv-04865-SJ-RLM Document 16 Filed 11/22/2005 Page 6 of 6

met by allowing the MDL Court to decide plaintiff's motion to remand."). "[A]ny prejudice to the plaintiff resulting from a stay would be minimal," Evans, 2005 WL 3008643, at *2, and "does not outweigh the judicial economy interests" served by granting a stay. Walker, 2005 WL 1565839, at *2; see North, 2005 WL 2921638, at *2; Krieger, 2005 WL 2921640, at *2. Therefore, Merck's motion for a stay is granted in its entirety.

CONCLUSION

For the foregoing reasons, Merck's motion to stay this proceeding pending the MDL Panel's decision on transfer is granted and plaintiff's cross-motion to remand is deferred until the issue of transfer has been resolved.

SO ORDERED.

**Dated: Brooklyn, New York
November 22, 2005**

**ROANNE L. MANN
UNITED STATES MAGISTRATE JUDGE**

Exhibit B

* * * * *

EXHIBIT C PAGE 11

PROCEEDINGS

(June 23, 2005)

THE DEPUTY CLERK: Everyone rise.

THE COURT: Be seated, please. Good morning, Ladies and Gentlemen. Call the case, please.

THE DEPUTY CLERK: MDL 1657, In Re: Vioxx.

THE COURT: Counsel, make your appearances for the record.

MR. SEEGER: Good morning, Your Honor. Chris Seeger for the plaintiffs. I'm going to be playing Russ Herman today.

MR. WITTMANN: Phil Wittmann, Your Honor, liaison counsel for the defendants.

THE COURT: I understand we have some counsel on the phone. Who is that?

MS. SOTOODEH: Pamela Sotoodeh in Chicago.

MS. KOPELMAN: Richard Kopelman of Decatur, Georgia.

THE COURT: Good morning. This is our monthly status conference. I have received from the liaison counsel the proposed agenda. We will take the items in order. The first is LexisNexis File & Serve. Let me have a report on that.

MR. SEEGER: Judge, we continue to have problems with LexisNexis. We are having problems getting documents posted and served. On the other end, they're having problems identifying firms that are already previously registered. We have got some calls set up with them to try to work through

1 some of these issues. We are hoping to be able to do that.

2 THE COURT: Let's get them in person in the court.
3 Let's do it next week. I will get my staff to give you a day.
4 I would like to see LexisNexis here, the president of the
5 company, or somebody who can talk with me about any problems.
6 I would like you all present to get this resolved. We need to
7 go on line as quickly as possible. We don't have time to have
8 to rely on surface mail. There are too many people in this
9 case. It really needs to be worked out.

10 I'm a little disappointed because LexisNexis
11 just took this over. I've had some experience with the people
12 from whom they bought this company and we didn't have any
13 problems with the prior group. I don't know why LexisNexis --
14 a bigger outfit, more resources -- is having problems when the
15 earlier group did not, so maybe they can help me understand
16 that.

17 MR. SEEGER: We will make arrangements to bring them
18 in.

19 THE COURT: Thank you.

20 MR. WITTMANN: Yes, Your Honor. We have not had
21 problems with LexisNexis. It seems, from the defendants'
22 standpoint, to be working okay. The few issues that have come
23 up, we have dealt directly with their representatives and they
24 have been responsive to our requests, so we are satisfied.
25 It's going okay from our standpoint.

1 If the Court please, we might give the folks a
2 statistical background on what's happening in the MDL at this
3 point. As of June 15, we had 907 cases in the MDL. Although
4 some of those cases have not yet been served on Merck, they are
5 here, 907 of them. There are over 700 Vioxx products liability
6 cases served and pending in federal court but not yet here.
7 There are over 170 cases served and pending in state courts
8 other than New Jersey and California. There are over 1,900
9 cases served and pending in the New Jersey consolidated
10 proceeding. There are approximately 180 cases pending in the
11 California state court, and those cases involve approximately
12 1,000 plaintiffs. That's our statistical update.

13 THE COURT: What about the numbers of class actions?

14 MR. WITTMANN: Class actions I believe are 118.
15 That's up about eight from our last status conference. We
16 either have provided or will provide copies of the additional
17 class action complaints to plaintiffs' counsel. Their deadline
18 for filing the master complaint, incidentally, is August 1.

19 THE COURT: Trial settings.

20 MR. WITTMANN: Yes, Your Honor. The first case that
21 we know that's set for trial is the Ernst case in Brazoria
22 County, Texas, on July 11, 2005. We have a case in New Jersey,
23 the Humeston case, which is set on September 12, 2005. The
24 Guerra case is set for trial in Hidalgo County, Texas, on
25 September 19, 2005. The Zajicek case is set for trial in

1 Jackson County, Texas, on September 26, 2005, but we are told
2 that's likely to be continued over to the first quarter of
3 2006. The Tomlin case is set for trial in Florida in St. Lucie
4 County sometime between October 3 and December 30, 2005. That
5 exact date has not been fixed yet. In addition to that, we
6 have a hearing set in the Engineers case in New Jersey on
7 June 30 to determine whether the court will certify a
8 nationwide case of third-party payors.

9 THE COURT: One of the challenges, from the
10 standpoint of the MDL, is to deal with cases not only
11 throughout the country in the federal system, but also cases
12 that are in the state system. One benefit of the MDL is
13 consistency and uniformity. The significance of uniformity and
14 consistency in the large numbers of cases is to allow you
15 folks, who are the lawyers in the cases, to be able to get a
16 read on matters so that hopefully you can evaluate the cases
17 and see whether or not there's any shorter way of dealing with
18 it, namely settlements or dealing with it in some motion way or
19 other evidence. Consistency or at least predictability is one
20 of the benefits of trials.

21 My concern oftentimes, if there are trials in
22 various jurisdictions, is that it doesn't afford the same
23 consistency if you had it in one jurisdiction, wherever it is.
24 It just gives you some more consistency and, therefore, more
25 predictability, and you're able to then learn from that

1 particular trial.

2 My hope was that we could begin trying cases in
3 the MDL as quickly as we can so that you can have that read and
4 benefit, but I do recognize that cases have been in state court
5 for about four years now. It's hard to have a litigant wait,
6 after they have done all the work in a particular case, and
7 then have to delay unduly. I have to measure both of those
8 things and weigh both of those things. I've been getting a lot
9 of good cooperation from the various state courts, and I think
10 that many of them feel the same way as I do. We will do the
11 best we can with it. In that regard, let me segue into the
12 next item, which is the selection of cases for an early trial
13 date in this particular proceeding.

14 MR. SEEGER: Judge, if you don't mind, on the last
15 point, just for the benefit of the lawyers reading the
16 transcript, we have requested of the defendant that going
17 forward, when they list the trial cases, that they give us the
18 name of the case, the court it's in, the attorney of record,
19 and if they can tell us what the injury is. I think that will
20 assist us in coordinating with those lawyers and help our state
21 federal liaison committee, as well.

22 THE COURT: Fine. We have got to watch from both
23 sides that cases are not tried before it's appropriate to try
24 them because that's going to skew the situation. It's not
25 going to help anybody to try a case that is either not

1 representative or that's not ready to be tried. It's going to
2 hurt the rest of your cases. Let's be conscious of that.

3 MR. WITTMANN: I think, in response to Chris' point,
4 we have been talking about Ernst and Humeston for a long time
5 now. I thought I had given that information to Russ, but we
6 will make sure he has it from now on.

7 THE COURT: Talk to me about trial dates for the
8 cases here.

9 MR. WITTMANN: Trial dates here, Judge, Mr. Herman
10 and I have been meeting and working on it ourselves. More
11 recently than that, Mr. Marvin has been meeting with Mr. Seeger
12 and others on the plaintiffs' steering committee to try and get
13 a pool of cases from which we can select cases for trial here
14 in the Eastern District. I would like to let Mr. Marvin
15 address that since he has been more familiar with the recent
16 negotiations than I have.

17 THE COURT: Okay.

18 MR. MARVIN: Good morning, Your Honor. Your Honor,
19 we have identified two pools of cases that could yield cases
20 for early trials. The first pool could come from the Eastern
21 District of Louisiana, where there are approximately 40 cases
22 presently on file. What we would need to do for those cases is
23 to have a short schedule for submission of the plaintiff fact
24 sheets so that both plaintiffs and defendants could look at
25 those cases and make some selections from those cases.

1 A second pool of cases, though, could come from
2 cases that have already been filed in the federal court and,
3 indeed, were filed even before the establishment of this MDL.
4 Discovery in a number of those cases has proceeded, and some to
5 an advanced stage. There are approximately 40 cases, for
6 example, where requests for interrogatories have been made,
7 answers have been given, plaintiff fact sheets have been
8 submitted, and medical records collected. That's an important
9 matter because collection of medical records could take several
10 months. So we do have 40 cases where we think that, working
11 with the plaintiffs, we can identify those cases. Those cases
12 would have objective criteria for the selection of those cases
13 because of the advanced discovery and, indeed, we would be
14 prepared to send our list of cases that we think would fit that
15 criteria within the next five days.

16 THE COURT: Let's do that in five days, then let me
17 hear from the plaintiffs in five days, and then we will meet
18 and pick the cases. The Eastern District cases I can try here.
19 The other cases that are put in from other states, even in the
20 federal system, in view of the Lexicon case I may have
21 difficulty trying them unless there's some stipulations. I can
22 do it in one of two ways. I can either try them with the
23 stipulations here or I can go to the area that the case
24 emanates from. An MDL judge sits throughout the country and is
25 able to do that. I can go to the other area.

1 The thing that you both have to look at is the
2 Circuit that you are dealing with because if I try them here,
3 even with stipulations, my understanding is the Fifth Circuit
4 will take the case from me in the appeal. If I try them in
5 another area, the circuit in that area will try it. I don't
6 know whether it's good or bad or whether people have feelings
7 one way or the other, but at least that's something for both
8 sides to consider when we talk about those cases.

9 MR. MARVIN: Fair enough.

10 THE COURT: Also, logistics, if I'm going to go some
11 other place, that area needs to know I'm going to be there, the
12 court space and the Marshals Service and things of that nature.

13 MR. MARVIN: Thank you, Your Honor. Once that list
14 is completed, we will continue working with the PLC to review
15 that list and hopefully come up with some cases.

16 THE COURT: After five days, if the plaintiffs can
17 get to me, I'll set a meeting. I will see both of you and pick
18 the cases.

19 MR. SEEGER: Judge, just a couple of brief comments
20 on this. We are all for getting a case scheduled for trial as
21 soon as possible. We like the November/December timeframe.
22 I'm not one of those lawyers and I don't think the attorneys on
23 the PSC are lawyers that believe we have to turn over every
24 document and every stone before we start trying a case.
25 However, I do want to make the Court aware of the fact that we

1 are trying to get discovery from the FDA and some third parties
2 and some remaining discovery from Merck that we would like to
3 get.

4 THE COURT: The early cases, if we are going to push
5 then as quickly as we can to make them meaningful, it's not
6 just to try the cases. It's to give both of you some idea of
7 how a jury feels about that particular case. First, I need
8 cases that are ready for trial. It's not going to do you any
9 good to try a case that's not ready for trial because whatever
10 the verdict is, somebody is going to have an excuse for it and
11 say, "Well, but for it being ready, it would have been
12 different," that sort of thing, whatever it is.

13 Secondly, I would like you to give some thought
14 to grouping them. If we are dealing with death cases, I don't
15 want to try all death cases because there are personal injury
16 cases, so we ought to try some cases that will give you some
17 benefit from the jury's view of that particular case. We need
18 cases that are ready and we need some variety.

19 MR. SEEGER: Thank you, Judge. With your comments in
20 mind, we will be talking with the defendants about potentially
21 a pool. We will be proposing cases, as well. Thank you.

22 THE COURT: Thank you. Class actions is the next
23 item on the agenda.

24 MR. WITTMANN: Yes, Your Honor. I have really
25 covered that already. I think it's on track in accordance with

1 the Pretrial Order governing class actions, and the plaintiffs
2 are due to file their master complaint or complaints by
3 August 1.

4 THE COURT: Okay. The discovery directed to Merck.

5 MR. WITTMANN: Yes, Your Honor. There are a couple
6 of facets to that. First of all, I don't think your Pretrial
7 Order on the individual cases is generally available yet, but
8 we have submitted an agreed Pretrial Order to you on the
9 individual cases. I understand you have signed it, but it
10 hasn't been posted yet.

11 THE COURT: I have signed it, yes.

12 MR. WITTMANN: There are two parts to that order.
13 The first part deals with the actual procedure for filing
14 motions and dealing with that process in the MDL. The second
15 part, which we suggested be designated "Pretrial Order __ A,"
16 if you recall, dealt with the actual review of prior discovery
17 produced by Merck in other cases. That process is ongoing.
18 The protocol for doing that is established by that Pretrial
19 Order and the parties are doing that now, even as we speak, up
20 in New Jersey.

21 We don't have any problems with respect to the
22 documents that have already been produced and the depositions
23 that have been taken. Those are being made available to the
24 plaintiffs' steering committee, and so far as I know that
25 process is going on without any problem. We have some

1 significant disputes with respect to the additional discovery
2 propounded by the plaintiffs' steering committee, both the
3 interrogatories and the document requests. It's our belief
4 they are overly broad. We have made that clear to the
5 plaintiffs' liaison counsel and plaintiffs' steering committee.
6 The parties have been working, trying to narrow those requests
7 to take into account the extent of which those requests are
8 duplicative of materials produced in other proceedings which
9 are being made available up in New Jersey.

10 We have set, by agreement with the plaintiffs'.
11 steering committee, I think a deadline of July 5 by which to
12 complete that meet-and-confer process to try and narrow down to
13 see if we can agree on what additional materials will or will
14 not be produced. If we are unsuccessful, then we will be in to
15 see Your Honor, I think, within 10 days after that.

16 THE COURT: Let me just make a couple of comments on
17 the discovery part. Discovery, particularly paper discovery,
18 is supposed to be helpful and not just stumbling blocks. The
19 purpose of discovery is to help you try your cases or get ready
20 for trial. If you get so tied into discovery, it gets to be so
21 voluminous and so time consuming and so burdensome that it saps
22 not only your energy, but your resources and your thinking and
23 sidetracks you, it is not good. It's got to be helpful. It
24 can't be just, "Let's get it because it's there," "Let's not
25 give it because we have got it." It's got to be helpful.

1 My thinking on discovery is that you all first
2 meet and share with each other a draft of what you need and
3 discuss it. If you can arrive at an agreement, that's fine.
4 If you can't arrive at an agreement, then before it's in final
5 form, talk to me about it. I'll tell you what my ruling will
6 be so we don't have to go back and forth. The plaintiffs don't
7 have to wait for 30 days to get a response, which is an
8 objection, and then they have to wait for another 30. We don't
9 have time to do that, so we have to streamline it. Get
10 together and see what you agree on. I don't have to be brought
11 into the agreement. The disagreements, bring me in and I will
12 resolve the disagreements. We will do it as quickly as we can.

13 MR. WITTMANN: Your Honor, are you saying that during
14 the course of our negotiations, if we do reach some impasse,
15 that you would welcome a conference call?

16 THE COURT: Get it to me right there and I'll resolve
17 the controversy.

18 MR. SEEGER: If Russ were here, he would have a great
19 quote from William Shakespeare something to the effect, "I've
20 never met a defendant that said a discovery request wasn't
21 burdensome," but having said that --

22 THE COURT: I'm sure Shakespeare said something like
23 that.

24 MR. SEEGER: In New York there's a guy named
25 Shakespeare who said something along those lines. The truth is

1 we served discovery. Merck has asked for a little bit more
2 time to continue discussing it. We are going to do that. We
3 are anxiously awaiting their response. There are no real
4 surprises in what we are asking for. As you said, Your Honor,
5 the case is being litigated. It has been litigated for a
6 while. I think we all know what we need.

7 THE COURT: Again, if you have already got some
8 material, let's work out something that if you've got it they
9 don't need to reproduce it. I know that sometimes you receive
10 some material that's case specific and this is noncase
11 specific, so you may need to go outside of that. If you have
12 got it, let's get on to something else. The Pretrial Order
13 governing individual cases.

14 MR. WITTMANN: Yes, Your Honor. You have those now.
15 There are actually two Pretrial Orders. One relates to the
16 production of documents in other cases, which is really a part
17 of the Pretrial Order for the individual cases.

18 THE COURT: I have that. I signed it. It should be
19 posted. Merck employee information is the next item. I have
20 briefs on that. I've set next Wednesday at 2:00 to have a
21 hearing on that oral argument on that question. The next item
22 is discovery directed to the FDA. How are we with that? We
23 had some misunderstandings. I got the FDA on the phone and
24 everybody was able to talk about it. I had the opportunity to
25 express my views. I haven't heard on it formally since then.

1 MR. SEEGER: Your Honor, my co-lead counsel,
2 Andy Birchfield, met with the FDA, so he is going to address
3 this issue.

4 MR. BIRCHFIELD: Your Honor, Russ Herman, Troy
5 Rafferty, and I met with the FDA with their counsel and with
6 the U.S. attorney Sharon Smith at the FDA headquarters in
7 Rockville, Maryland. We discussed the items on the subpoena
8 and we were able to reach agreement on a number of those
9 issues. We have continuing dialogue on some of the others.
10 The important thing was that we were able to at least get the
11 discovery process, the review process, and the production
12 process moving while we are continuing dialogue. They have
13 agreed to provide us with the first page of the documents that
14 were produced in Congress so we can review those and identify
15 which ones we actually need. They have also agreed to start
16 the production. We expect by the end of July to get the
17 initial production. They will continue that on a rolling
18 basis. We are making considerable progress on the FDA
19 production.

20 THE COURT: I should express the Court's appreciation
21 to the chair of the FDA. I appreciate his help. He should
22 know that I am obliged to him for getting involved in this
23 matter and helping us move forward. I do publicly appreciate
24 his help.

25 MR. BIRCHFIELD: One other thing on that. Merck,

1 Ben Barnett, was also there. There is cooperation there. They
2 are agreeing to provide a list of documents that are between
3 the FDA and Merck so we can review that list and determine
4 which ones need to be produced and which ones we already have.

5 THE COURT: Thank you very much. Discovery directed
6 to third parties is the next item.

7 MR. SEEGER: Your Honor, we are in the next couple of
8 days going to get out probably about a dozen or so subpoenas to
9 third parties. We are going to try to stage it in a way so we
10 do it in phases, but at this point there's not much to report
11 other than we are going to get the subpoenas out.

12 THE COURT: Let's keep that on the agenda so that you
13 can talk to me about it next time. We really ought to work
14 through that. That's an important part. Deposition
15 scheduling.

16 MR. WITTMANN: The first and third weeks of the
17 month, Judge, were set by prior Pretrial Order. We had sent a
18 request to the plaintiffs' steering committee last week asking
19 that depositions be set in some of the Louisiana cases starting
20 the first week in July or, alternatively, the third week in
21 July, depending upon what they were able to pull together from
22 their clients. We left the selection of the plaintiffs to be
23 deposed to the plaintiffs' steering committee because we are
24 trying to accommodate the individual plaintiffs and not just go
25 out and arbitrarily pick dates and select them. Your Honor has

17

1 told us in our prior Pretrial Order that we are to cooperate in
2 trying to arrange a mutually agreeable date before running out
3 and setting depositions by notice.

4 We have not heard back. I understand from the
5 plaintiffs' steering committee this morning that the cases that
6 we have selected may not be suitable for the early trials in
7 this Court, so we are waiting to get a list, really, of the
8 cases that we think will go forward for an early trial and will
9 set them for deposition as soon as we can.

10 THE COURT: Okay. Let's keep an eye on prioritizing.
11 There's some issues that might cut across the spectrum. You
12 may want to take depositions of individuals that have something
13 to say about the general theories so they will be significant
14 in each case, but with regard to case-specific discovery I
15 think you should focus on the cases that we select for trial
16 and do those. Now, that doesn't mean that you only have to
17 have one wave of depositions. You can have a couple of tracks
18 going on. You have to be able to do several tracks at the same
19 time in a case like this.

20 MR. SEEGER: You just anticipated my comments. We
21 think that the depositions of plaintiffs should somehow
22 dovetail with what we are doing on trial schedules, although I
23 would like to correct the record. I don't have any opinion on
24 whether cases by any other lawyer are appropriate for trial or
25 not. I think we have to come up with a criteria for selecting

1 cases that will inform decisions that may be made down the road
2 between the parties.

3 THE COURT: The next item is the plaintiffs' profile
4 form and Merck's profile form. I understand from the parties
5 that with regard to the plaintiffs' profile form they have
6 reached an agreement. On Merck's profile form, they have not
7 reached an agreement. Each side submitted to me their
8 disagreements and I have resolved the conflict. I'll be today
9 putting out the defendants' profile form that will be used in
10 this case. That will be resolved.

11 Also, with the profile forms of both sides, it
12 seems to me that we ought to do that in waves. The first wave,
13 I would like both the plaintiffs and the defendants to focus on
14 and limit the forms to the cardiovascular events -- the
15 myocardial infarctions, the ischemic strokes, the deaths -- and
16 then shortly thereafter, when we get some experience with those
17 forms and with filling them out and any problems, in resolving
18 those problems we ought to be able to step it out quickly to
19 the second wave, which may not require as detailed information.
20 It seems to me to be the best way of doing it. I put some
21 handwritten notes on this form and I will simply adopt it in an
22 order and give you my thinking on that particular form. The
23 plaintiffs will have to redraft the form and submit it.
24 Medical records from healthcare providers is the next item.

25 MR. SEEGER: Judge, I think that we have agreed on a

1 procedure for having medical records posted online almost
2 identical to what we are doing in New Jersey for plaintiffs'
3 lawyers as well as defense counsel to have access to records in
4 a secure way. I think that's been accomplished.

5 MR. WITTMANN: That's correct, Your Honor.

6 THE COURT: Contact with claimants' healthcare
7 providers. That's the subject of another motion. I received
8 briefs for reconsideration on that issue. I'll be hearing that
9 in oral argument on Wednesday, also. The plaintiffs'
10 depository is the next item on the agenda.

11 MR. SEEGER: We are happy to report we are up and
12 running. We have got it staffed and it is available to
13 plaintiffs' lawyers who want to come look at documents and
14 contribute to the document review. We welcome the help.

15 THE COURT: Talk with the defendants. If they have
16 no objection, I would like to at least look at the depository,
17 if that's possible, just see that it's up and running and so
18 forth.

19 MR. WITTMANN: That's no problem, Judge, whenever
20 counsel wants to set it up.

21 THE COURT: Set it up and we'll take a look at it.
22 The confidentiality agreement is the next one.

23 MR. WITTMANN: That's been signed. Your Honor, I
24 haven't had any problems with it. We had one question as to
25 whether some of the material that was attached to I believe the

1 brief filed by the state liaison committee may have contained
2 some confidential information. I don't believe it really did,
3 but the time hasn't yet run for us to designate. We are still
4 looking at that. We may have some comment about it. I don't
5 think it's a major problem.

6 THE COURT: That's an issue always of concern and
7 it's a balancing issue. It's a balancing issue between the
8 First and Sixth Amendments. The First Amendment, of course,
9 the right of the public to know, it's vital in a democracy that
10 the public know. It's also vital in a democracy that people
11 have every right to a fair trial. There's some conflict
12 occasionally between the First and the Sixth Amendment. The
13 way that it's worked out, in my judgment, in a fair way is to
14 not deprive the public of a right to know, but perhaps delay
15 the public's information, unless it is a critical type of
16 information which is necessary for immediate knowledge.

17 I'm focused, instead, on the right to a fair
18 trial for both sides, and there is certain proprietary
19 information in these documents that drug companies
20 realistically and legitimately get concerned about releasing,
21 proprietary information that could affect their present or
22 future business practices. I am conscious of the public's
23 right to know, but I am also conscious of the fact that if I
24 don't have a confidentiality order, then it delays the
25 discovery and delays trials and delays justice. I have dealt

1 with this issue in that fashion. We have a confidentiality
2 agreement which will allow the defendants comfort to produce
3 certain information without fear that their future economic
4 security is in jeopardy. The remand issues.

5 MR. SEEGER: Judge, that's in the report. You are
6 going to be dealing with remand motions as a group by
7 procedures that you will be setting up.

8 THE COURT: Right. This is always an issue which the
9 MDL Court has to look at. The question is posed. There are
10 various issues of remand in various cases throughout the
11 country. Again, a significant advantage of the MDL concept is
12 some consistency. The Rule of Law is really based on
13 consistency. If different decisions are made by numerous
14 judges, then you have no consistency and no predictability and
15 no one knows exactly what to do or how to do it. It's easier
16 if one court decides some of these matters than if 50 or 100
17 courts decide the matter.

18 I'm conscious of dealing with the remand as
19 quickly as possible, but I do want to get them all together,
20 look at them, see if I can group them in some way, and then
21 direct my attention on each particular group and deal with that
22 issue in a consistent and fair fashion for that group. I will
23 be dealing with them as quickly as I can, but also with an idea
24 of having more consistency. I'll be speaking about this
25 perhaps later on because I do have some concepts and ideas

1 about this. Tolling agreements is the next item.

2 MR. SEEGER: Judge, just to report that we have
3 accomplished our goal. It was a long negotiation, but we got
4 it resolved. Both sides have compromised and agreed on a
5 tolling agreement. It seems to be working. We are getting
6 cases in.

7 MR. WITTMANN: The agreement was filed, I guess, on
8 the 9th of this month, so it's just recently been filed, but
9 we are starting to get people taking advantage of it. We are
10 getting the short form exhibits mailed in. We have a procedure
11 set up by the defendants to respond to those exhibits as they
12 come in. We are keeping a record of them so we know exactly
13 where we stand with respect to the people who have elected to
14 go forward on the tolling agreements, Your Honor.

15 THE COURT: I appreciate the help on both sides on
16 the tolling agreements. I think it's good for each side. I
17 think there's different advantages, but advantages for each
18 side, and I think it will be helpful to you. Certainly, I
19 think it will be helpful to the litigants. The next item is
20 state/federal coordination. State liaison committee, are there
21 things that you want to say?

22 MS. BARRIOS: Yes, Your Honor. We have been fairly
23 active since our last meeting here. At the Court's order, we
24 were allowed to file a brief on the issue of the Merck employee
25 information. We did that and I question, Your Honor, if you

1 would like us to be present at the hearing on Wednesday to make
2 a presentation?

3 THE COURT: Sure. You are always welcome to
4 participate in a hearing.

5 MS. BARRIOS: Thank you, Your Honor.

6 THE COURT: I'm interested in your views. I have
7 looked at the brief. A lot of it has already been said. I
8 don't think I need any response from the defendants on it. I
9 think you have covered it in your particular response. Let's
10 keep that in mind. I know that oftentimes you see matters in
11 the same fashion as perhaps the plaintiffs' steering committee.

12 MS. BARRIOS: Yes, Your Honor.

13 THE COURT: If you do, just "Me, too" it. I don't
14 need you to restate it. That's sufficient. If you see it in a
15 different light, just carve that out. If I need some response,
16 I will direct the defendants to give me a response on it.

17 MS. BARRIOS: Yes, sir. We have no intention of
18 being duplicative. With the cooperation of Mr. Wittmann's
19 office and Mr. Herman's office, we have received a roster of
20 over 700 plaintiffs' attorneys names. We sent out our first
21 very lengthy newsletter detailing the orders, the web site,
22 etc. We have gotten extremely good feedback from different
23 plaintiffs' attorneys across the country on it. We have had
24 several conference calls with our committee. Mr. Witkin on our
25 committee made a presentation at the Mealey's seminar about the

1 MDL yesterday. We met with the PSC last night and look forward
2 to working with them to reserve the rights of the plaintiffs'
3 attorneys and their clients.

4 THE COURT: I appreciate all of your interest and
5 work and willingness to work on the committee. It's very
6 important. I know there's some interests that are different.
7 That's the way of the world. There's some joint interests and
8 so rather than reinvent the wheel and do things a second time,
9 third time, fourth time, it is helpful for you to be in the
10 development of it so that you can just migrate that information
11 into your proceedings so you don't have to redo it again.

12 MS. BARRIOS: Yes, Your Honor. Thank you.

13 MR. SEEGER: From the PSC's perspective, we have
14 enjoyed the working relationship with the committee. We think
15 the lawyers on the committee are of extremely high quality.
16 They have been proactive in anticipating issues. We welcome
17 their input on anything we do. We did have dinner last night,
18 had a chance to talk through some important issues before we
19 poured the first bottle of wine -- which was helpful -- and we
20 are looking forward to the continued cooperation between our
21 committee and theirs.

22 THE COURT: The waiver of service is the next item.

23 MR. WITTMANN: Yes, Your Honor. You have the
24 Pretrial Order in effect on that. I think it's Pretrial
25 Order 15, and we haven't had any problems.

1 THE COURT: The next item is direct filing into the
2 MDL. Ms. Loretta Whyte was kind enough to meet with us earlier
3 today to discuss that in more detail. The issue, of course, is
4 whether or not the party who files directly into the MDL should
5 have the MDL caption or should have their independent caption.
6 Ms. Whyte tells us that the best way of doing it, from her
7 vantage point, is to have an individual caption just as you
8 would if you file a regular case, but put on that "Related
9 Case, MDL" and give the number. She will then migrate it into
10 the MDL proceedings. That will be the best way of doing that.
11 Is that right, Ms. Whyte?

12 MS. WHYTE: Yes.

13 MR. SEEGER: There's one thing on that issue that's
14 important to note for people reading the transcript. There's
15 been some confusion whether the lawyers need to be admitted
16 pro hac to file cases.

17 THE COURT: They do not need to be admitted pro hac.
18 I have waived that. Anybody who's in the MDL or has a case in
19 the MDL is able to handle a matter.

20 MR. SEEGER: Just to be clear, Ms. Whyte, the cases
21 that get filed must mention the Vioxx MDL and that it's a
22 related case?

23 MS. WHYTE: It's a related case.

24 THE COURT: Anything further on that? Pro se
25 claimants.

1 MR. SEEGER: Well, Your Honor, we have been referring
2 what we have been getting from the Court to our plaintiffs'
3 liaison counsel and these are being dealt with.

4 THE COURT: I think we have a system of doing it. So
5 far most of the pro se claimants have been individuals who have
6 not been able to be personally present at these meetings. They
7 are generally incarcerated some other place and can't make it
8 here, so they need a lawyer. They have expressed their
9 interest in being represented, so I have given that to liaison
10 counsel. I understand that what they do is contact lawyers in
11 the state of that particular institution and make those lawyers
12 available to them, or at least tell them that they would be
13 available. That seems to be working.

14 Anything further from anyone that I haven't
15 covered before I set the next status conference date? Anything
16 either from the state committee, liaison committee, or anyone
17 in the audience? I'm interested in hearing your views.

18 MR. WITTMANN: Nothing from the defendants,
19 Your Honor.

20 MR. SEEGER: Nothing further from plaintiffs,
21 Your Honor.

22 MS. BARRIOS: Nothing further.

23 MR. BECNEL: Judge, I have a lawyer who has referred
24 me 160 cases from Oregon. I have dealt with Mr. Wittmann's
25 associate, Ms. Wimberly. He wants to bring them all here, but

1 because of the peculiar law in Oregon he is starting to have to
2 file them right away in Oregon. I'm trying to get some sort of
3 a deal with the defendants to get them all here without missing
4 a statute problem. I'm just wondering how we can work that
5 out.

6 MR. WITTMANN: We are working that out now, actually,
7 Your Honor, with a procedure for the filing of a master
8 complaint in the MDL that will permit people to come in and tag
9 along and sign on with the short form joinder pleading, which
10 should take care of Mr. Becnel's problem.

11 THE COURT: Mr. Seeger, get with Mr. Becnel and see
12 if we can handle this particular problem.

13 MR. SEEGER: Yes, Your Honor.

14 MR. GIRARDI: Tom Girardi, Your Honor.

15 THE COURT: Mr. Girardi.

16 MR. GIRARDI: Your Honor, we now have a state court
17 judge for the 2,000 cases in California. I will provide you
18 with that contact information, Judge Chaney.

19 THE COURT: Please do that because I am trying to
20 keep in touch with the state court judges. When we begin
21 setting some Daubert hearings or other hearings, if they wish
22 to come in the case, we will do either the voice or do video
23 streaming so that they can participate and deal with it
24 according to their law, but they won't have to retake the
25 witnesses. If they have any questions, they can ask the

1 questions while the witnesses are there, so I would like to
2 know that. Thank you.

3 MR. SEEGER: Just for the record, if I could ask
4 Mr. Girardi to copy liaison counsel on that?

5 MR. GIRARDI: Yes.

6 THE COURT: Anything else? The next status
7 conference is Tuesday, July 19, 9:30. I'll meet with the
8 liaison counsel in my chambers at 8:00 that day to begin
9 getting ready for this meeting. I appreciate everybody's
10 cooperation and for their reports. Thank you. Court will
11 stand in recess.

12 THE DEPUTY CLERK: Everyone rise.

13 (WHEREUPON, the Court was in recess.)
14

15 * * *

16 CERTIFICATE

17 I, Toni Doyle Tusa, CCR, Official Court Reporter,
18 United States District Court, Eastern District of Louisiana, do
19 hereby certify that the foregoing is a true and correct
20 transcript, to the best of my ability and understanding, from
21 the record of the proceedings in the above-entitled and
22 numbered matter.

23 Toni Doyle Tusa
24 Toni Doyle Tusa, CCR
25 Official Court Reporter




Exhibit C

JUN. 9. 2005 5:34PM

JPML

NO. 4277 P. 2/2

UNITED STATES OF AMERICA
JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

CHAIRMAN:

Judge Wm. Terrell Hodges
United States District Court
Middle District of Florida

MEMBERS:

Judge John F. Keenan
United States District Court
Southern District of New York

Judge D. Lowell Jensen
United States District Court
Northern District of California

Judge J. Frederick Motz
United States District Court
District of Maryland

Judge Robert L. Miller, Jr.
United States District Court
Northern District of Indiana

Judge Kathryn M. Vrzag
United States District Court
District of Kansas

Judge David R. Hansen
United States Court of Appeals
Eighth Circuit

Robert A. Cahn
Executive Attorney

DIRECT REPLY TO:

Michael J. Beck
Clerk of the Panel
One Columbus Circle, NE
Thurgood Marshall Federal
Judiciary Building
Room O-255, North Lobby
Washington, D.C. 20002

Telephone: (202) 502-2800
Fax: (202) 502-2838

<http://www.jpml.uscourts.gov>

March 21, 2005

Honorable Ricardo H. Hinojosa
U.S. District Judge
1701 W Bus Highway 83
Bentsen Tower, Suite 1028
McAllen, TX 78501

Re: MDL-1657—In re Vioxx Products Liability Litigation

Felicia Garza, et al. v. Merck & Co., Inc., et al., S.D. Texas, C.A. No. 7:05-17

Dear Judge Hinojosa:

Presently before the Panel pursuant to 28 U.S.C. § 1407 is a notice of opposition to the Panel's conditional transfer order in the above matter pending before you. The parties will have an opportunity to fully brief the question of transfer and the matter will be considered at a bimonthly Panel hearing session. In the meantime, your jurisdiction continues until any transfer ruling becomes effective.

If you have a motion pending – such as a motion to remand to state court (if the action was removed to your court) – you are free to rule on the motion, of course, or wait until the Panel has decided the transfer issue. The latter course may be especially appropriate if the motion raises questions likely to arise in other actions in the transferee court and, in the interest of uniformity, might best be decided there if the Panel orders centralization.

Please feel free to contact our staff in Washington with any questions.

Kindest regards,



Wm. Terrell Hodges
Chairman

Exhibit D

02/29/2008 19:44 212-403-5663

DLA PIPER US LLP

PAGE 22/40

Clerk of the Court. A facsimile copy of this Stipulation shall have the same effect as the original.

Dated: New York, New York
March 5, 2008

LAW OFFICE OF RONALD R. BENJAMIN

By: 

Ronald R. Benjamin
126 Riverside Drive
P.O. Box 607
Binghamton, New York 13902-0607
607-772-1442

Attorneys for Plaintiff

DLA PIPER US LLP

By: 

Christopher M. Strongosky
Tiffany L. Christian
1251 Avenue of the Americas
New York, NY 10020-1104
212-335-4500

Attorneys for Pfizer Defendants

HUGHES HUBBARD & REED LLP

By: _____

Vilia B. Hayes
One Battery Park Plaza
New York, NY 10004-1482
212-837-6000

Attorneys for Merck & Co., Inc.

08 17 21 FAX

HH&R LLP 11W

004/028

03/03/2008 11:33 212-403-5553

DLA PIPER US LLP

PAGE 05/31

Clerk of the Court. A facsimile copy of this Stipulation shall have the same effect as the original.

Dated: New York, New York
March 4, 2008

LAW OFFICE OF RONALD R. BENJAMIN

DLA PIPER US LLP

By: _____
Ronald R. Benjamin
126 Riverside Drive
P.O. Box 607
Binghamton, New York 13902-0607
607-772-1442

By: _____
Christopher M. Strongosky
Tiffany L. Christian
1251 Avenue of the Americas
New York, NY 10020-1104
212-335-4500

Attorneys for Plaintiff

Attorneys for Pfizer Defendants

HUGHES HUBBARD & REED LLP

By: *Vilia B. Hayes*
Vilia B. Hayes
One Battery Park Plaza
New York, NY 10004-1482
212-837-6000

Attorneys for Merck & Co., Inc.

Exhibit E

SUB # 23

SUPREME COURT OF THE STATE OF NEW YORK
COUNTY OF NEW YORK-----X
: Index No. 560001/2005
: IN RE: NEW YORK BEXTRA AND CELEBREX
: CASE MANAGEMENT
: PRODUCT LIABILITY LITIGATION
: ORDER NO. 6
:-----X-----X
: THIS DOCUMENT APPLIES TO ALL CASES
:-----X**FILED**

AUG 16 2006

Plaintiff Fact Sheets And Defendant Fact Sheets**I. Applicability And Scope Of Order**NEW YORK
COUNTY CLERK'S OFFICE

1. This Order governs certain pretrial procedures for cases involving the prescription medications Bextra and Celebrex which are presently or hereafter assigned to this Court ("Coordinated Proceeding"). This Order shall apply to all Plaintiffs who allegedly suffered personal injury from taking Bextra and/or Celebrex in cases currently pending in or that have been or will be originally filed in, or transferred to, this Court and assigned thereto. This Order is binding on all parties and their counsel in all cases currently pending or subsequently made part of these proceedings.

II. Plaintiff Fact Sheets, Documents And Authorizations

2. Plaintiffs' Obligation To Serve Plaintiff Fact Sheets and Responsive Documents.

a. Applicable Plaintiff Fact Sheet. Each individual Plaintiff bound by this Order shall serve upon Defendants' counsel a complete and signed Plaintiff Fact Sheet ("PFS") in the forms set forth in Attachments A (Bextra-only Plaintiffs), B (Celebrex-only Plaintiffs), or C (Plaintiffs who allege taking both Bextra and Celebrex) pursuant to the schedule ordered in paragraph 5 herein. If a Plaintiff initially completes Attachment A or B hereto and

medical records or other information subsequently reveal that Plaintiff took both Bextra and Celebrex, such Plaintiff shall provide the additional information contained in Attachment C within sixty (60) days upon request by any Defendant. Each PFS shall be mailed to Defendants' counsel as follows:

Loren H. Brown
Raymond M. Williams
Attn: Bextra/Celebrex—NY COORD. PROC.
DLA PIPER RUDNICK GRAY CARY US LLP
1251 Avenue of the Americas
New York, New York 10020

b. Responsive Documents. The Plaintiff shall also produce with his or her PFS all documents responsive to the document requests contained therein ("responsive documents"). If neither Plaintiff nor Plaintiff's counsel possess responsive documents, Plaintiff's counsel must inform Defendants' counsel of such in writing concurrently with serving the PFS.

c. Answers Binding As If Interrogatory Responses And Signed Under Penalty Of Perjury. All responses in a PFS are binding on the Plaintiff as if they were contained in responses to interrogatories. Each PFS shall be signed and dated by the Plaintiff or the proper Plaintiff representative under penalty of perjury.

d. Plaintiffs Suing In Representative Or Derivative Capacity. If the Plaintiff is suing in a representative or derivative capacity (e.g., on behalf of an estate, as a survivor, and/or as an assignee or subrogee), the completed PFS and produced responsive documents must provide information about the individual who allegedly took Celebrex and/or Bextra.

3. Plaintiffs' Obligation To Serve HIPAA-Compliant Authorizations.

a. Five Blank Medical Authorizations Served With PFS. Each individual Plaintiff subject to this Order shall serve upon Defendants' counsel designated above along with his or her PFS and responsive documents five originals of the "Authorization for the Release of Medical Records" for all health care providers and other sources of information and records (including but not limited to pharmacies, insurance companies, and/or any applicable state or federal government agencies) (collectively, "custodian of records") in forms as agreed upon by Plaintiffs' and Defendants' Liaison Counsel and contained in CMO No. 7. The "Authorization for the Release of Medical Records" shall distinguish between Plaintiffs asserting no psychological injury and Plaintiffs asserting psychological injury, and each individual Plaintiff shall serve the version that is applicable to that individual Plaintiff. The authorizations shall be dated and signed without setting forth the identity of the custodian of the records or provider of care.

b. Three Blank Employment Authorizations Served With PFS. Each individual Plaintiff subject to this Order shall serve upon Defendants' counsel designated above along with his or her PFS and responsive documents three originals of the "Authorization for the Release of Employment Records" for all employers in forms to be agreed upon by Plaintiffs' and Defendants' Liaison Counsel with respect to Plaintiffs asserting no wage loss claim and Plaintiffs asserting a wage loss claim. The authorizations shall be dated and signed without setting forth the identity of the employer.

c. Custodian-Specific Updated Or Additional Authorizations. If a health care provider, employer, or other custodian of records: (i) has a specific authorization form it requires its patients to use, (ii) requires a more recent authorization than the

authorizations initially provided by Plaintiff, (iii) requires a notarized authorization, or (iv) requires an original signature and the record collection company or companies jointly retained by the parties have already used all original authorizations provided by Plaintiff, then the record collection company or companies retained by the parties shall so notify Plaintiff's counsel and provide such specific authorization(s) and/or new blank authorization(s) to Plaintiff's counsel. Plaintiff shall execute such specific, updated and/or original authorization(s) within thirty (30) days and pursuant to paragraph 3.d. herein, where applicable. Where Plaintiff identifies one of the custodians of record listed in Attachment D hereto in his or her Plaintiff Fact Sheet, such Plaintiff shall execute the applicable custodian-specific authorization for that custodian and provide such authorization along with his or her Plaintiff Fact Sheet, blank authorizations and responsive documents. Plaintiffs' Liaison Counsel shall make the custodian-specific authorizations for the custodians listed in Attachment D available to Plaintiffs' counsel.

d. Plaintiffs Suing In Representative Or Derivative Capacity. If the Plaintiff is suing in a representative or derivative capacity, the authorizations must be signed and produced along with documentation, if any exists, establishing that the signatory is a duly appointed representative or is otherwise permitted to execute authorizations on behalf of the person who allegedly took Celebrex and/or Bextra.

4. Use Of Authorizations.

a. Custodians Listed In PFS. Any record collection company or companies jointly retained by the parties may use the authorizations (including copies of the original blank authorizations) for any health care provider, employer, or other custodian of records identified in the PFS without further notice to the Plaintiff's counsel. Any Plaintiff who has an objection to the collection of records from any health care provider, employer, or other

custodian of records identified in the PFS shall make such objection to Defendants at the time the PFS is provided, or else any such objection to the use of the authorization is waived. This provision shall not waive any right that an individual may have to request the return of the records, to challenge the admissibility of the records, or to otherwise move the Court for appropriate relief.

b. Custodians Not Listed In PFS. If the Defendants wish to use an authorization to obtain records from a custodian that is not identified in the PFS, the record collection company or companies jointly retained by the parties shall provide the Plaintiff's counsel for that particular case with seven days written notice (by facsimile) of the intent to use an authorization to obtain records from that custodian. If Plaintiff's counsel fails to object to the request within seven days (by facsimile), the retained record collection company or companies may use the authorization to request the records from the custodian identified in the notice. If Plaintiff's counsel objects to the use of the authorization to obtain records from the custodian identified in the notice within said seven-day period, such objection must be served on Defendants' counsel designated above in writing (by facsimile) and must identify the legal basis for the objection and describe the nature of the documents to which the objection is asserted in a manner that, without revealing the information allegedly protected, will enable the Defendants to assess the applicability of the asserted protection.

5. Schedule For Serving Plaintiff Fact Sheets, Responsive Documents And Authorizations. Plaintiffs in cases filed prior to the date of entry of this Order shall have sixty (60) days from the date of entry of this Order to serve upon Defendants' counsel designated above a complete and signed PFS, all responsive documents (or a written notice that none are in the possession of Plaintiff or Plaintiff's counsel) and properly executed authorizations. Each

Plaintiff in cases that are filed in the New York Unified Court System and that are or will be subject to this Coordinated Proceeding after the date of entry of this Order shall serve upon Defendants' counsel designated above a complete and signed PFS, all responsive documents (or a written notice that none are in the possession of Plaintiff or Plaintiff's counsel) and properly executed authorizations within sixty (60) days from the date of filing. For the purpose of this paragraph, the "date of filing" is defined as the date on which the case is filed in the New York Unified Court System. Notwithstanding the provisions of this paragraph, in cases that have been filed but where the complaint has not been served upon Defendants, Defendants' receipt of a PFS, responsive documents, authorizations or other such materials served under this paragraph shall not constitute or be deemed consent to personal jurisdiction or a waiver of any service requirement in such cases under applicable law.

6. Provision Of Medical Records To Parties. Plaintiffs' and Defendants' Liaison Counsel shall make available, through an outside vendor(s) jointly selected and hired by Liaison Counsel, all records obtained from any health care provider(s) or other custodian(s) of records through an authorization or subpoena on a secure web site maintained by the outside vendor(s). Such records shall be Bates numbered by the vendor. Plaintiff's counsel in a specific case may access that web site to obtain copies of their clients' records only, and are hereby restricted from accessing or obtaining copies of any other individual's medical records through that web site or vendor. For each set of records Plaintiffs' counsel (or counsel for any other party) wishes to obtain from the vendor(s), Plaintiffs or the other party may be charged any one-time "viewing fees" established by the vendor(s) and agreed to by the parties, plus half of any fee charged by the records custodian, which shall be payable directly to the vendor(s). If a third party (for example, a treating physician defendant or other third party or, as the case may be, a

Plaintiff) also wishes to obtain the records, that party shall be charged one-third of the fee charged by the record custodian, and one-third of the fee paid by each earlier party who obtained the records shall be refunded by the vendor(s). Plaintiffs (or counsel for any other party) will be able to download and copy any and all viewed records for their use at no additional expense. The Defendants shall have no other obligation to provide medical or other records obtained pursuant to the authorization(s) to Plaintiffs, including prior to the deposition of any Plaintiff.

III. Dismissal Of Plaintiffs' Claims For Failure To Comply With Discovery Obligations

7. Notice That Claims May Be Dismissed. Any Plaintiff who fails to comply with any discovery obligations imposed by this Order within the time periods set forth herein may be subject to having his or her claims, as well as any derivative claim(s), dismissed if good cause for such dismissal is shown. Good cause shall exist where there is a material deficiency in responding to required discovery, i.e., one that prejudices Defendants through a failure to provide necessary information, thereby impeding Defendants' access to material and relevant evidence. Any dismissal may be with or without prejudice as the Court may determine in an individual case. Defendants have informed the Court that they intend to move to dismiss with prejudice those cases in which there is a material deficiency in responding to required discovery. The procedure for such motions shall be governed by paragraph 10 herein.

8. Initial Notice Of Discovery Obligations.

a. Notice By Court To Be Jointly Drafted By Parties. Plaintiffs' and Defendants' Liaison Counsel shall meet and confer to draft a notice from the Court to Plaintiffs' counsel regarding the Coordinated Proceeding, which such notice shall describe the status of the litigation, the Plaintiffs' discovery obligations, and any other duties imposed by the Court's various Case Management Orders and which shall enclose copies of the Case Management

Orders applicable to all cases ("the Initial Notice"). Liaison Counsel shall update the Initial Notice from time to time as they see fit or as ordered by the Court. Plaintiffs' Liaison Counsel shall be responsible for transmitting the Initial Notice to Plaintiffs' counsel.

b. Cases Presently Pending In The Coordinated Proceeding. The Initial Notice provided to Plaintiffs' counsel in all cases pending in this Coordinated Proceeding as of the date of this Order shall inform Plaintiffs' counsel in the subject cases that, pursuant to this Case Management Order, Plaintiffs have sixty (60) days to serve upon Defendants' counsel designated above a complete and signed PFS, all responsive documents (or a written notice that none are in the possession of Plaintiff or Plaintiff's counsel) and properly executed authorizations.

c. Cases Subsequently Filed And Transferred. The Initial Notice provided to Plaintiffs' counsel in all cases transferred to or directly filed in this Coordinated Proceeding after the date of this Order shall inform Plaintiffs' counsel that, pursuant to this Case Management Order, Plaintiffs have sixty (60) days from the date of service or the date of transfer as defined in paragraph 5 above to serve upon Defendants' counsel designated above a complete and signed PFS, all responsive documents (or a written notice that none are in the possession of Plaintiff or Plaintiff's counsel), and properly executed authorizations.

9. Notice Of Overdue Or Deficient Discovery. When any Plaintiff has failed to materially comply with their obligations under this Order within the timelines established herein, Defendants' Liaison Counsel or her designee shall send a notice of the material deficiency to the Plaintiff's counsel for the individual whose responses are alleged to be defective ("the deficiency letter"). The deficiency letter shall identify with particularity the alleged material deficiency, state that the Plaintiff will have thirty (30) days to cure the alleged

material deficiency, and state that absent the alleged material deficiency being cured within that time (or within any extension of that time as agreed to by the parties), Defendants may move for dismissal of Plaintiff's claims, including dismissal with prejudice upon an appropriate showing. Plaintiffs' Liaison Counsel or his designee shall be electronically copied with the deficiency letter. This provision shall not be construed to prevent Defendants' Liaison Counsel or her designee from meeting and conferring with Plaintiffs' Liaison Counsel regarding any other deficiencies.

10. Procedure For Dismissal Of Cases With Material Deficiency. The procedure for the motions referenced in paragraph 7 shall be as follows:

- a. If Plaintiff's individual counsel responds to the deficiency letter, Defendants' Liaison Counsel or her designee shall meet and confer with such counsel with respect to the purported deficiency.
- b. If the parties' meet and confer is unsuccessful, or if Plaintiff's individual counsel does not respond to the deficiency letter and a subsequent meet and confer effort under New York Rules of Court § 202.7 (22 N.Y.C.R.R. 202.7), Defendants' Liaison Counsel or her designee may file a motion (a "compliance motion") with the Special Master (appointed by the Court to hear such disputes) seeking a report and recommendation requiring Plaintiff to comply with this Order within twenty-one (21) days, or face a dismissal motion to be filed with the Court, including dismissal with prejudice, or other sanctions.
- c. Such compliance motion shall be heard on an expedited basis. A compliance motion may be noticed twenty-one (21) calendar days before the hearing date, with any opposition to be filed ten (10) calendar days before the hearing and any reply to be filed five (5) calendar days before the hearing.

d. If the Special Master appointed by the Court to hear such disputes determines that Plaintiff's discovery is materially deficient, it shall issue a report and recommendation requiring Plaintiff to comply with this Order within twenty-one (21) days ("the compliance order"), or face dismissal or other appropriate sanctions, as determined by the Court.

e. If Plaintiff does not comply with the compliance order within twenty-one (21) days, Defendants' Liaison Counsel or her designee may file a motion with the Court to dismiss Plaintiff's claims with prejudice or for other appropriate sanctions (a "dismissal/sanctions motion").

f. Such dismissal/sanctions motion shall be heard on an expedited basis. A dismissal motion may be noticed twenty-one (21) calendar days before the hearing date, with any opposition to be filed ten (10) calendar days before the hearing and any reply to be filed five (5) calendar days before the hearing.

g. If the Court determines that Plaintiff has not complied with the compliance order, it may dismiss Plaintiff's claims with or without prejudice, or impose other sanctions, as it deems appropriate.

IV. Defendant Fact Sheet

11. Pfizer Entities' Obligation To Serve Defendant Fact Sheet. Defendants Pfizer Inc., Pharmacia & Upjohn Co., Pharmacia & Upjohn LLC, Pharmacia Corporation, and G.D. Searle LLC (formerly known as G.D. Searle & Co.) (collectively, "the Pfizer Entities"), shall collectively serve upon each Plaintiff's counsel of record (as identified in the PFS) a hard copy of a complete and verified Defendant Fact Sheet in the form set forth in Attachment E. An electronic copy of the Defendant Fact Sheet shall also be served on Plaintiffs' Liaison Counsel's

designee and individual counsel for each Plaintiff for whom an email address has been provided in the Plaintiff Fact Sheet.

12. Schedule For Serving Defendant Fact Sheet. The Pfizer Entities shall provide a complete and verified Defendant Fact Sheet within sixty (60) days after receipt of a substantially complete and verified PFS and substantially complete authorizations, or within sixty (60) days after service of the complaint, whichever is later. If the Pfizer Entities fail to provide a completed and verified Defendant Fact Sheet within that time, Plaintiffs' Liaison Counsel shall provide notice to Defendants' Liaison Counsel by facsimile as provided in paragraph 13 herein. The Pfizer Entities shall have an additional thirty (30) days to cure the deficiency. No other extensions will be granted, absent good cause.

13. Notice Of Overdue Or Deficient Discovery. In the event that the Pfizer Entities have failed to materially comply with their obligations under this Order within the timelines established herein, Plaintiffs' Liaison Counsel shall send a notice of the material deficiency to the Defendants' Liaison Counsel. The notice shall identify with particularity the alleged material deficiency, state that the Pfizer Entities will have thirty (30) days to cure the alleged material deficiency, and state that absent the alleged material deficiency being cured within that time (or within any extension of that time as agreed to by the parties), Plaintiffs' Liaison Counsel may, after meeting and conferring with Defendants' Liaison Counsel, move the Court or Special Master appointed by the Court to hear such disputes for evidentiary or other sanctions. This provision shall not be construed to prevent Plaintiffs' Liaison Counsel or her designee from meeting and conferring with Defendants' Liaison Counsel regarding any other deficiencies.

14. Notice That Court May Impose Sanctions. If the Pfizer Entities fail to comply with any discovery obligations imposed by this Order within the time periods set forth herein, the Pfizer Entities may be subject to such evidentiary or other sanctions as this Court (or Special Master appointed by the Court to hear such disputes) may see fit to impose, upon motion by Plaintiffs' Liaison Counsel, after meeting and conferring with Defendants' Liaison Counsel, if good cause for such sanctions is shown. Good cause shall exist where there is a material deficiency in responding to required discovery, i.e., one that prejudices Plaintiff through a failure to provide necessary information, thereby impeding Plaintiff's access to material and relevant evidence.

V. Other Discovery

15. Case-Specific Discovery. The parties shall meet and confer regarding a further schedule for discovery, a protocol for the selection of certain cases for an initial trial pool of cases to be initially addressed by this Court and case-specific depositions as to those cases.

16. Generic Experts. The parties shall meet and confer regarding the subject of generic expert discovery. The term "generic experts" refers to experts who will testify on issues of general or widespread applicability, including but not limited to those who will testify on general causation. The parties shall meet and confer to agree upon timing for the identification of generic experts, the number of generic experts, the contents of generic experts' reports and the schedule for generic expert discovery and *Daubert* / *Frye* motions.

FILED

SO ORDERED.

AUG 16 2006

Dated: 8/14, 2006

NEW YORK
COUNTY CLERK'S OFFICE


Hon. Shirley W. Kornreich
SHIRLEY WERNER KORNREICH
J.S.C.

7987997v7

Exhibit F

SUPREME COURT OF THE STATE OF NEW YORK
COUNTY OF NEW YORK-----X
MARIANNE RAFTIS,

Plaintiff,

- against -

Index No.: 111297/06

PFIZER, INC., PHARMACIA CORPORATION, a
wholly-owned subsidiary of PFIZER, INC.,
and PHARMACIA & UPJOHN COMPANY, a wholly-
owned subsidiary of PHARMACIA CORPORATION,
and MERCK & CO., INC.,Defendants.
-----X**PLAINTIFF PROFILE FORM**

Other than in Sections I (B), those questions using the term "You" should refer to the person who used VIOXX®. Please attach as many sheets of paper as necessary to fully answer these questions.

I. CASE INFORMATION

- A. Name of person completing this form: MARIANNE E. RAFTIS
- B. If you are completing this questionnaire in a representative capacity (e.g., on behalf of the estate of a deceased person or a minor), please complete the following:
1. Social Security Number: _____
 2. Maiden or other names used or by which you have been known: _____
 3. Address: _____
 4. State which individual or estate you are representing, and in what capacity you are representing the individual or estate? _____
 5. If you were appointed as a representative by a court, state the:
Court: _____ Date of Appointment: _____
 6. What is your relationship to deceased or represented person or person claimed to be injured? _____
 7. If you represent a decedent's estate, state the date of death of the decedent and the address of the place where the decedent died:

C. Claim Information

1. Are you claiming that you have or may develop bodily injury as a result of taking VIOXX®?
Yes X No _____ If "yes,"

a. What is your understanding of the bodily injury you claim resulted from your use of VIOXX®? Heart attack

b. When do you claim this injury occurred? August 13, 2003

c. Who diagnosed the condition? Erich Schneider, M.D., or Paul Traverse, M.D.

d. Did you ever suffer this type of injury prior to the date set forth in answer to the prior question? Yes _____ No X If "yes," when and who diagnosed the condition at that time? _____

e. Do you claim that your use of VIOXX® worsened a condition that you already had or had in the past? Yes _____ No X If "yes," set forth the injury or condition; whether or not you had already recovered from that injury or condition before you took VIOXX®; and the date of recovery, if any.

D. Are you claiming mental and/or emotional damages as a consequence of VIOXX®?
Yes _____ No X

If "yes," for each provider (including but not limited to primary care physician, psychiatrist, psychologist, counselor) from whom have sought treatment for psychological, psychiatric or emotional problems during the last ten (10) years, state:

a. Name and address of each person who treated you: None

b. To your understanding, condition for which treated: _____

c. When treated: _____

d. Medications prescribed or recommended by provider: _____

II. PERSONAL INFORMATION OF THE PERSON WHO USED VIOXX®

A. Name: MARIANNE F. RAFTIS

B. Maiden or other names used or by which you have been known: Fox

C. Social Security Number: 082-16-9202

D. Address: 100 Franklin Street, Owego, NY 13827

E. Identify each address at which you have resided during the last ten (10) years, and list when you started and stopped living at each one:

Address	Dates of Residence
100 Franklin Street, Owego, NY 13827	1957 to present

F. Driver's License Number and State Issuing License: _____

G. Date and Place of Birth: July 5, 1919

H. Sex: Male ☐ Female ☒

- I. Identify the highest level of education (high school, college, university or other educational institution) you have attended (even if not completed), the dates of attendance, courses of study pursued, and diplomas or degrees awarded:

Institution	Dates Attended	Course of Study	Diploma or Degree
Gloversville High School Gloversville, New York	grad 1936		grad
Green Mountain Junior College Poultney, Vermont	37-38		BA
Hartwick College Oneonta	38-40	Business	BS
State University at Albany	1999	Business/Teaching	Masters Degree

J. Employment Information.

1. Current employer (if not currently employed, last employer):

Name	Address	Dates of Employment	Occupation/Job Duties
Retired			
Owego Free Academy		1985-1982	Taught Business

2. List the following for each employer you have had in the last ten (10) years:

Name	Address	Dates of Employment	Occupation/Job Duties
None			

3. Are you making a wage loss claim for either your present or previous employment?

Yes ☐ No ☒

If "yes," state your annual income at the time of the injury alleged in

Section IC: _____

K. Military Service Information: Have you ever served in the military, including the military reserve or national guard? Yes _____ No X

If "yes," were you ever rejected or discharged from military service for any reason relating to your physical, psychiatric or emotional condition? Yes _____ No _____

L. Insurance / Claim Information:

1. Have you ever filed a worker's compensation and/or social security disability (SSI or SSD) claim? Yes _____ No X If "yes," to the best of your knowledge please state:

a. Year claim was filed: _____

b. Nature of disability: _____

c. Approximate period of disability: _____

2. Have you ever been out of work for more than thirty (30) days for reasons related to your health (other than pregnancy)? Yes _____ No _____ If "yes," set forth when and the reason. _____

3. Have you ever filed a lawsuit or made a claim, other than in the present suit, relating to any bodily injury? Yes _____ No _____ If "yes," state to the best of your knowledge the court in which such action was filed, case name and/or names of adverse parties, and a brief description for the claims asserted. _____

M. As an adult, have you been convicted of, or plead guilty to, a felony and/or crime of fraud or dishonesty? Yes _____ No X If "yes," set forth where, when and the felony and/or crime. _____

III. FAMILY INFORMATION

A. List for each marriage:

1. The name of your spouse Robert R. Raftis

2. Spouse's date of birth (for your current spouse only) Deceased

3. Spouse's occupation Deceased

4. Date of marriage June 24, 1943

5. Date the marriage ended, if applicable _____

6. How the marriage ended (e.g., divorce, annulment, death): Death of husband

B. Has your spouse filed a loss of consortium claim in this action? Yes X No _____

C. To the best of your knowledge did any child, parent, sibling, or grandparent of yours suffer from any type of cardiovascular disease including but not limited to: heart attack, abnormal rhythm, arteriosclerosis (hardening of the arteries), murmur, coronary artery disease, congestive heart failure,

enlarged heart, leaking valves or prolapse, heart block, congenital heart abnormality, scarlet fever, rheumatic fever, atrial fibrillation, stroke?

Yes _____ No X Don't Know _____ If "yes," identify each such person below and provide the information requested.

Name: _____
 Current Age (or Age at Death): _____
 Type of Problem: _____
 If Applicable, Cause of Death: _____

D. If applicable, for each of your children, list his/her name, age and address:

Margaret Raftis, 10/13/48, 523 Paden Street, Endicott, NY 13760 ; Patricianne Pacatte, 12/17/41, P.O. Box 305, Howes Cave, NY 12092-9701; Pamela Green, 02/23/43, 112 Franklin Street, Owego, NY 13827; Mary Penelope Sharrow, 01/25/51, 625 Jay Street, Ogdensburg, NY 13669; Michael Raftis, 08/03/54, 3550 Smith Drive, Endwell, NY 13760; Martin Raftis, 05/10/58, 46 Seymour Street, Auburn, NY 13021

E. If you are claiming the wrongful death of a family member, list any and all heirs of the decedent. Not applicable

IV. VIOXX® PRESCRIPTION INFORMATION

- A. Who prescribed VIOXX® for you? Thomas J. Oven, M.D., and Susan Choi, M.D.
- B. On which dates did you begin to take, and stop taking, VIOXX®?
Began: 3/9/01 Stopped: 11/25/03
- C. Did you take VIOXX® continuously during that period? Yes X No _____ Don't recall _____
- D. To your understanding, for what condition were you prescribed VIOXX®? Arthritis knee pain
- E. Did you renew your prescription for VIOXX®? Yes X No _____ Don't recall _____
- F. If you received any samples of VIOXX®, state who provided them, what dosage, how much and when they were provided: _____
- G. Which form of VIOXX® did you take (check all that apply)?
 _____ 12.5 mg Tablet (round, cream, MRK 74)
 _____ 12.5 mg Oral Suspension
X 25 mg Tablet (round, yellow, MRK 110)
 _____ 25 mg Oral Suspension
 _____ 50 mg Tablet (round, orange, MRK 114)
- H. How many times per day did you take VIOXX®? Once per day

I. Did you request that any doctor or clinic provide you with VIOXX® or a prescription for VIOXX®?
Yes _____ No X Don't recall _____

J. Instructions or Warnings:

1. Did you receive any written or oral information about VIOXX® before you took it?
Yes _____ No _____ Don't Recall X- Probably received something from the drug store

2. Did you receive any written or oral information about VIOXX® while you took it?
Yes _____ No _____ Don't Recall X- Probably received something from the drug store

3. If "yes,"

- When did you receive that information? _____
- From whom did you receive it? _____
- What information did you receive? _____

K. What over-the-counter pain relief medications, if any, were you taking at the same time you were taking VIOXX®? _____

V. MEDICAL BACKGROUND

A. Height: _____

B. Current Weight: _____ lbs.
Weight at the time of the injury, illness, or disability described in Section I(C): _____ lbs.

C. Smoking/Tobacco Use History: *Check the answer and fill in the blanks applicable to your history of smoking and/or tobacco use.*

_____ Never smoked cigarettes/cigars/pipe tobacco or used chewing tobacco/snuff.

_____ Past smoker of cigarettes/cigars/pipe tobacco or used chewing tobacco/snuff.

a. Date on which smoking/tobacco use ceased: _____

b. Amount smoked or used: on average _____ per day for _____ years.

X Current smoker of cigarettes/cigars/pipe tobacco or user of chewing tobacco/snuff.

a. Amount smoked or used: on average 3-4 per day for 69 years.

_____ Smoked different amounts at different times.

D. Drinking History. Do you now drink or have you in the past drank alcohol (beer, wine, whiskey, etc.)?
Yes X No _____ If "yes," fill in the appropriate blank with the number of drinks that represents your average alcohol consumption during the period you were taking VIOXX® up to the time that you sustained the injuries alleged in the complaint:

3-4 drinks per week,

_____ drinks per month,

_____ drinks per year, or

_____ Other (describe): _____

- E. Illicit Drugs. Have you ever used (even one time) any illicit drugs of any kind within one (1) year before, or any time after, you first experienced your alleged VIOXX®-related injury?"

Yes _____ No X Don't recall _____ If "yes", identify each substance and state when you first and last used it.

- F. Please indicate to the best of your knowledge whether you have ever received any of the following treatments or diagnostic procedures:

1. Cardiovascular surgeries, including, but not limited to, the following, and specify for what condition the surgery was performed: open heart/bypass surgery, pacemaker implantation, vascular surgery, IVC filter placement, carotid (neck artery) surgery, lung resection, intestinal surgery:

Surgery	Condition	When	Treating Physician	Hospital

2. Treatments/interventions for heart attack, angina (chest pain), or lung ailments:

Treatment/Intervention	When	Treating Physician	Hospital
Cardiac catheterization	8/13/03	Erich Schneider, M.D.	Wilson Memorial

3. To your knowledge, have you had any of the following tests performed: chest Xray, CT scan, MRI, angiogram, EKG, echocardiogram, TEE (trans-esophageal echo), bleeding scan, endoscopy, lung bronchoscopy, carotid duplex/ultrasound, MRI/MRA of the head/neck, angiogram of the head/neck, CT scan of the head, bubble/microbubble study, or Holter monitor?

Yes X No _____ Don't Recall _____ If "yes," answer the following:

Diagnostic Test	When	Treating Physician	Hospital	Reason
MRI left coronary system	8/13/03	Paul W. Traverse, MD	Wilson Memorial	Heart attack
Chest X-ray	11/24/03		Lourdes	
Electrocardiogram	11/24/03		Lourdes	
Cardiac rehab/monitor	1/7/04-1/26/04		Lourdes	Cardiac symptoms
13 Weeks cardiac rehab	late 2003-early 2004	Erich Schneider, M.D.	Lourdes	Heart Attack

VI. DOCUMENTS

Please indicate if any of the following documents and things are currently in your possession, custody, or control, or in the possession, custody, or control of your lawyers by checking "yes" or "no." Where you have indicated "yes," please attach the documents and things to your responses to this profile form.

- A. Records of physicians, hospitals, pharmacies, and other healthcare providers identified in response to this profile form. Yes X No
- B. Decedent's death certificate (if applicable). Yes No
- C. Report of autopsy of decedent (if applicable). Yes No

VII. LIST OF MEDICAL PROVIDERS AND OTHER SOURCES OF INFORMATION

List the name and address of each of the following:

A. Your current family and/or primary care physician:

Name	Address
Susan Choi, M.D.	Guthrie Clinic, 3 Tioga Boulevard, Apalachin, NY 13732

B. To the best of your ability, identify each of your primary care physicians for the last ten (10) years.

Name	Address	Approximate Dates
Susan Choi, M.D.	Guthrie Clinic, 3 Tioga Boulevard, Apalachin, NY 13732	1987-present

C. Each hospital, clinic, or healthcare facility where you have received inpatient treatment or been admitted as a patient during the last ten (10) years.

Name	Address	Admission Dates	Reason for Admission
Wilson Memorial Hospital	33-35 Harrison Street Johnson City, NY 13790	8/13-8/15/03	Heart attack

D. Each hospital, clinic, or healthcare facility where you have received outpatient treatment (including treatment in an emergency room) during the last ten (10) years.

Name	Address	Admission Dates	Reason for Admission
Lourdes Hospital	169 Riverside Drive Binghamton, NY 13905	11/24/03	Cardiac symptoms
Emergency Medicine Robert Packer Hospital	Sayre, PA 18840	April 2004	Carpal Tunnel Operation

E. Each physician or healthcare provider from whom you have received treatment in the last ten (10) years.

Name	Address	Dates of Treatment
Thomas J. Oven, M.D.	161 Riverside Drive, Binghamton, NY 13905	11/99 - 2004
Erich Schneider, M.D.	161 Riverside Drive, Binghamton, NY 13905 (no longer in practice)	8/13/03 - 7/04
Ghassem Mangouri, M.D.	355 Riverside Drive Johnson City, NY 13790	3/04-hernia operation Lourdes
Charles R. Fedele, M.D.	Robert Packer Hospital, Sayre, Pa. 18840	1998 - 1999
Susan W. Choi, M.D.	Guthrie Clinic, 3 Tioga Boulevard Apalachin, NY 13732	1998-2004

Terence M. Devine, M.D.	Guthrie Ophthalmology 2517 Vestal Parkway East, Vestal, NY	April 2004
Poni S. Bishop, M.D.	Emergency Medicine Robert Packer Hospital, Sayre, PA 18840	4/25/04
Paul W. Traverse, M.D.	Wilson Memorial Hospital	8/13/03 - present
Jeffrey Pokorny, M.D.	Guthrie Healthcare Systems Guthrie Square, Sayre, PA 18840	8/04 - 9/04
Joseph A. Scopelliti, M.D.	Guthrie Healthcare Systems Guthrie Square, Sayre, PA 18840	6/27/03 - present

F. Each pharmacy that has dispensed medication to you in the last ten (10) years.

Name	Address
CVS Pharmacy #2252	39 Park Street, Owego, NY 13827

G. If you have submitted a claim for social security disability benefits in the last ten (10) years, state the name and address of the office that is most likely to have records concerning your claim.

Name	Address

H. If you have submitted a claim for worker's compensation, state the name and address of the entity that is most likely to have records concerning your claim.

Name	Address

CERTIFICATION

I declare under penalty of perjury subject to N.Y. C.P.L.R. 3133(b) (McKinney 2005) that all of the information provided in this Profile Form is true and correct to the best of my knowledge, that I have completed the List of Medical Providers and Other Sources of Information appended hereto, which is true and correct to the best of my knowledge, that I have supplied all the documents requested in part VI of this declaration, to the extent that such documents are in my possession, custody, or control, or in the possession, custody, or control of my lawyers, and that I have supplied the authorizations attached to this declaration.

Marianne J. Raftis
Signature

MARIANNE J. RAFTIS
Print Name

16 October 2007
Date

Exhibit G

CVS PHARMACY
Patient Prescription Record
01/01/1998 THRU 12/15/2004
PHARMACY # 2252

PAGE: 4 of 5
RUN DATE: 12/17/2004
REQUEST NR: 113093

PHARMACY NAME:
ADDRESS:
CITY, ST, ZIP:

PATIENT KEY:
PATIENT NAME:
ADDRESS:
CITY, ST, ZIP:

TELEPHONE: 607-687-3273
BIRTHDATE: 07/05/1919

CVS PHARMACY #2252
39 PARK STREET
OMEGA NY 13827

22523121
RAFFIS MARIANNE
100 FRANKLIN ST
OMEGA NY 13827

RX NUMBER	REL NUMBER	DRUG DESCRIPTION	PRESCRIBER NAME	DATE FILLED	SPH INT	QUANT DISP.	PRIMARY FAYER #	SCOPY LAYER #	TOTAL PRICE	PRIMARY 2D AMT	SCOPY 2D AMT	SCOPY 2D AMT	SCOPY 2D AMT
188189	1	00006011063 VIOXX 25MG TABLET	OVEN, THOMA J	04/22/2003	PC	30	7434		76.08	69.08			
188189	2	00006011063 VIOXX 25MG TABLET	OVEN, THOMA J	07/01/2003	PG	30	7434		79.60	71.60			
188189	3	00006011063 VIOXX 25MG TABLET	OVEN, THOMA J	09/29/2003	LG	30	7434		79.60	71.60			
188189	4	00006011063 VIOXX 25MG TABLET	OVEN, THOMA J	11/25/2003	LG	30	7434		79.60	71.60			
190510	0	0000603144 FOSMAX 70MG TABLET	OVEN, THOMA J	04/22/2003	PC	12	7434		186.04	179.04			
190510	1	0000603144 FOSMAX 70MG TABLET	OVEN, THOMA J	08/20/2003	PC	12	7434		186.04	179.04			
194594	0	00379151001 DICLOXONINE 10MG CAPSULE	SCOPPELLITI, JOSEF	06/21/2003	PC	60	7434		9.92	9.92			
194594	1	00379151001 DICLOXONINE 10MG CAPSULE	SCOPPELLITI, JOSEF	09/08/2003	LG	60	7434		9.92	9.92			
194594	2	00379151001 DICLOXONINE 10MG CAPSULE	SCOPPELLITI, JOSEF	10/14/2003	LG	60	7434		9.92	9.92			
194594	3	00379151001 DICLOXONINE 10MG CAPSULE	SCOPPELLITI, JOSEF	12/31/2003	FG	60	7434		9.92	9.92			
197497	0	00378021801 ATTENDOL 25MG TABLET	TRAVERSE, PAUL M	08/15/2003	LG	30	7434		4.63	4.63			
197497	1	00378021801 ATTENDOL 25MG TABLET	TRAVERSE, PAUL M	09/28/2003	LG	30	7434		4.63	4.63			
197497	2	00378021801 ATTENDOL 25MG TABLET	TRAVERSE, PAUL M	10/14/2003	LG	30	7434		4.63	4.63			
197497	3	00378021801 ATTENDOL 25MG TABLET	TRAVERSE, PAUL M	11/10/2003	LG	30	7434		4.63	4.63			
197498	0	61570011201 ALTACE 5MG CAPSULE	TRAVERSE, PAUL M	08/15/2003	LG	30	7434		39.92	31.92			
197498	1	61570011201 ALTACE 5MG CAPSULE	TRAVERSE, PAUL M	09/08/2003	LG	30	7434		39.92	31.92			
197498	2	61570011201 ALTACE 5MG CAPSULE	TRAVERSE, PAUL M	10/14/2003	LG	30	7434		39.92	31.92			
197498	3	61570011201 ALTACE 5MG CAPSULE	TRAVERSE, PAUL M	11/10/2003	PC	30	7434		39.92	31.92			
197498	4	61570011201 ALTACE 5MG CAPSULE	TRAVERSE, PAUL M	12/16/2003	IS	30	7434		42.15	34.15			
197498	5	61570011201 ALTACE 5MG CAPSULE	TRAVERSE, PAUL M	01/15/2004	PC	30	7434		63.77	61.77			
197499	0	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	06/15/2003	LG	30	7434		63.77	61.77			
197499	1	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	09/09/2003	LG	30	7434		63.77	61.77			
197499	2	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	10/14/2003	LG	30	7434		63.77	61.77			
197499	3	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	11/10/2003	PC	30	7434		63.77	61.77			
197499	4	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	12/16/2003	IS	30	7434		63.77	61.77			
197499	5	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	01/15/2004	PC	30	7434		63.77	61.77			
197499	6	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	06/15/2003	LG	30	7434		63.77	61.77			
197499	7	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	09/09/2003	LG	30	7434		63.77	61.77			
197499	8	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	10/14/2003	LG	30	7434		63.77	61.77			
197499	9	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	11/10/2003	PC	30	7434		63.77	61.77			
197499	10	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	12/16/2003	IS	30	7434		63.77	61.77			
197499	11	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	01/15/2004	PC	30	7434		63.77	61.77			
197499	12	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	06/15/2003	LG	30	7434		63.77	61.77			
197499	13	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	09/09/2003	LG	30	7434		63.77	61.77			
197499	14	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	10/14/2003	LG	30	7434		63.77	61.77			
197499	15	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	11/10/2003	PC	30	7434		63.77	61.77			
197499	16	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	12/16/2003	IS	30	7434		63.77	61.77			
197499	17	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	01/15/2004	PC	30	7434		63.77	61.77			
197499	18	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	06/15/2003	LG	30	7434		63.77	61.77			
197499	19	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	09/09/2003	LG	30	7434		63.77	61.77			
197499	20	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	10/14/2003	LG	30	7434		63.77	61.77			
197499	21	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	11/10/2003	PC	30	7434		63.77	61.77			
197499	22	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	12/16/2003	IS	30	7434		63.77	61.77			
197499	23	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	01/15/2004	PC	30	7434		63.77	61.77			
197499	24	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	06/15/2003	LG	30	7434		63.77	61.77			
197499	25	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	09/09/2003	LG	30	7434		63.77	61.77			
197499	26	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	10/14/2003	LG	30	7434		63.77	61.77			
197499	27	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	11/10/2003	PC	30	7434		63.77	61.77			
197499	28	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	12/16/2003	IS	30	7434		63.77	61.77			
197499	29	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	01/15/2004	PC	30	7434		63.77	61.77			
197499	30	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	06/15/2003	LG	30	7434		63.77	61.77			
197499	31	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	09/09/2003	LG	30	7434		63.77	61.77			
197499	32	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	10/14/2003	LG	30	7434		63.77	61.77			
197499	33	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	11/10/2003	PC	30	7434		63.77	61.77			
197499	34	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	12/16/2003	IS	30	7434		63.77	61.77			
197499	35	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	01/15/2004	PC	30	7434		63.77	61.77			
197499	36	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	06/15/2003	LG	30	7434		63.77	61.77			
197499	37	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	09/09/2003	LG	30	7434		63.77	61.77			
197499	38	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	10/14/2003	LG	30	7434		63.77	61.77			
197499	39	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	11/10/2003	PC	30	7434		63.77	61.77			
197499	40	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	12/16/2003	IS	30	7434		63.77	61.77			
197499	41	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	01/15/2004	PC	30	7434		63.77	61.77			
197499	42	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	06/15/2003	LG	30	7434		63.77	61.77			
197499	43	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	09/09/2003	LG	30	7434		63.77	61.77			
197499	44	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	10/14/2003	LG	30	7434		63.77	61.77			
197499	45	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	11/10/2003	PC	30	7434		63.77	61.77			
197499	46	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	12/16/2003	IS	30	7434		63.77	61.77			
197499	47	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	01/15/2004	PC	30	7434		63.77	61.77			
197499	48	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	06/15/2003	LG	30	7434		63.77	61.77			
197499	49	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	09/09/2003	LG	30	7434		63.77	61.77			
197499	50	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	10/14/2003	LG	30	7434		63.77	61.77			
197499	51	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	11/10/2003	PC	30	7434		63.77	61.77			
197499	52	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	12/16/2003	IS	30	7434		63.77	61.77			
197499	53	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	01/15/2004	PC	30	7434		63.77	61.77			
197499	54	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	06/15/2003	LG	30	7434		63.77	61.77			
197499	55	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	09/09/2003	LG	30	7434		63.77	61.77			
197499	56	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	10/14/2003	LG	30	7434		63.77	61.77			
197499	57	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	11/10/2003	PC	30	7434		63.77	61.77			
197499	58	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	12/16/2003	IS	30	7434		63.77	61.77			
197499	59	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	01/15/2004	PC	30	7434		63.77	61.77			
197499	60	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	06/15/2003	LG	30	7434		63.77	61.77			
197499	61	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	09/09/2003	LG	30	7434		63.77	61.77			
197499	62	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	10/14/2003	LG	30	7434		63.77	61.77			
197499	63	00306073531 ZOCOR 10MG TABLET	TRAVERSE, PAUL M	11/10/2003	PC	30	7434		63.77	61.77			
1974													

PHARMACY NAME: CVS PHARMACY #2252
ADDRESS: 39 PARK STREET
CITY, ST, ZIP: OREGO NY 13827

PATIENT KEY: 22523121
PATIENT NAME: RAFTIS MARIANNE
ADDRESS: 100 FRANKLIN ST
CITY, ST, ZIP: OREGO NY 13827

TELEPHONE: 607-697-3273
BIRTHDATE: 07/05/1919

CVS PHARMACY
Patient Prescription Record
01/01/1998 THRU 12/31/2004
PHARMACY # 2252

PAGE: 2 of 6
RUN DATE: 12/17/2004
REQUEST NAME: 1130923

FA NUMBER	REL NUMBER	DRUG DESCRIPTION	PRESCRIBER NAME	DATE FILLED	RPH INT	QUANT DISP.	PRIMARY FAVOR #	SCORRY FAVOR #	TOTAL PRICE	PRIMARY PD AMT	SCORRY PD AMT	PATIENT PD AMT
110916	3	00066995030 NORITATE 1% CREAM	FEDDELE, CHARL R	06/10/1999	PC	30	7434		33.44	26.14		5.00
112465	0	00071006720 ORNICEF 300MG CAPSULE	METCALFE, ANTHO	02/02/1999	LG	20	7400		60.96	35.96		5.00
120709	0	5167129006 HYDROCHLORISONE 0.2% CREAM	CHOI, SUSAN	09/29/1999	KM	45	7434		21.23	21.23		5.00
121862	0	00009454102 DETROL 1MG TABLET	CHOI, SUSAN	10/13/1999	LG	60	7434		69.52	63.52		5.00
121689	0	00073150616 NASACORT AQ NASAL SPRAY	CHOI, SUSAN	10/13/1999	LG	17	7434		30.90	33.90		5.00
121699	1	00073150616 NASACORT AQ NASAL SPRAY	CHOI, SUSAN	12/10/1999	LG	17	7434		30.90	33.90		5.00
122359	0	0006995030 NORITATE 1% CREAM	FEDDELE, CHARL R	10/29/1999	LG	30	7434		35.90	30.90		5.00
122359	1	0006995030 NORITATE 1% CREAM	FEDDELE, CHARL R	12/10/1999	LG	30	7434		35.90	30.90		5.00
122360	0	00160008031 HYDROCHLORISONE 2.5% CREAM	FEDDELE, CHARL R	10/29/1999	LG	30	7434		7.01	7.01		5.00
122998	0	00025152531 CELERBREX 200MG CAPSULE	CHOI, SUSAN	11/13/1999	LG	30	7434		65.91	60.91		5.00
122998	1	00025152531 CELERBREX 200MG CAPSULE	CHOI, SUSAN	12/07/1999	LG	30	7434		65.91	60.91		5.00
124898	0	00060925531 FOSAMAX 5MG TABLET	CHOI, SUSAN	02/07/2000	PC	30	7434		55.72	50.72		5.00
124898	1	00060925531 FOSAMAX 5MG TABLET	CHOI, SUSAN	03/01/2000	LG	30	7434		55.72	50.72		5.00
124898	2	00060925531 FOSAMAX 5MG TABLET	CHOI, SUSAN	04/01/2000	LG	30	7434		55.72	50.72		5.00
124898	3	00060925531 FOSAMAX 5MG TABLET	CHOI, SUSAN	06/05/2000	LG	30	7434		55.72	50.72		5.00
124898	4	00060925531 FOSAMAX 5MG TABLET	CHOI, SUSAN	08/09/2000	PC	30	7434		65.91	60.91		5.00
126094	0	00025152531 CELERBREX 200MG CAPSULE	CHOI, SUSAN	02/29/2000	PC	30	7434		65.91	60.91		5.00
126094	1	00025152531 CELERBREX 200MG CAPSULE	CHOI, SUSAN	04/01/2000	LG	30	7434		65.91	60.91		5.00
126094	2	00025152531 CELERBREX 200MG CAPSULE	CHOI, SUSAN	04/24/2000	LG	30	7434		65.91	60.91		5.00
130413	0	00025152531 CELERBREX 200MG CAPSULE	CHOI, SUSAN	06/05/2000	LG	30	7434		65.91	60.91		5.00
130413	1	00025152531 CELERBREX 200MG CAPSULE	CHOI, SUSAN	07/12/2000	PC	30	7434		65.91	60.91		5.00
130413	2	00025152531 CELERBREX 200MG CAPSULE	CHOI, SUSAN	08/21/2000	PC	21	7434		12.07	10.07		5.00
135554	0	00160008031 HYDROCHLORISONE 2.5% CREAM	CHOI, SUSAN	08/21/2000	PC	30	7434		3.53	1.53		5.00
135554	0	00160008031 HYDROCHLORISONE 2.5% CREAM	CHOI, SUSAN	11/05/2000	PC	40	7434		13.49	11.49		5.00
135554	0	000930493025 PROPOXY-NE/APR 100-650 TA	WHITLOCK, RITA-C	11/05/2000	PC	30	7434		60.30	55.30		5.00
135554	0	000930493025 PROPOXY-NE/APR 100-650 TA	WHITLOCK, RITA-C	12/09/2000	LG	30	7434		60.30	55.30		5.00
135554	0	000930493025 PROPOXY-NE/APR 100-650 TA	WHITLOCK, RITA-C	01/04/2001	PC	28	7434		4.81	2.81		5.00
143976	0	0006011068 VIOXX 25MG TABLET	LALLON, ROBERT T	01/30/2001	PC	15	7434		36.99	31.49		5.00
143979	0	00143071001 PACORONED 100MG CAPSULE	CHOI, SUSAN	01/30/2001	PC	14	7434		22.72	17.72		5.00
144939	0	00071053023 ACCURET 10MG TABLET	CHOI, SUSAN	02/14/2001	LG	30	7434		30.13	25.13		5.00
144939	1	00071053023 ACCURET 10MG TABLET	CHOI, SUSAN	04/13/2001	PC	20	7434		30.13	25.13		5.00
145752	0	00071053023 ACCURET 10MG TABLET	CHOI, SUSAN	03/01/2001	PC	30	7434		71.22	66.22		5.00
146173	0	0006011068 VIOXX 25MG TABLET	O'DEN, THOMA J	04/11/2001	LG	30	7434		71.22	66.22		5.00
146173	1	0006011068 VIOXX 25MG TABLET	O'DEN, THOMA J	05/23/2001	LG	30	7434		71.22	66.22		5.00
146173	2	0006011068 VIOXX 25MG TABLET	O'DEN, THOMA J	06/23/2001	LG	30	7434		71.22	66.22		5.00
146173	3	0006011068 VIOXX 25MG TABLET	O'DEN, THOMA J	07/18/2001	LG	30	7434		71.22	66.22		5.00
146173	4	0006011068 VIOXX 25MG TABLET	O'DEN, THOMA J		LG	30	7434					5.00

CVS PHARMACY
Patient Prescription Record
01/01/1998 THRU 12/15/2004
PHARMACY # 2252

PAGE: 2 of 6
RUN DATE: 12/17/2004
REQUEST NBR: 1130937

PHARMACY NAME: CVS PHARMACY #2252
ADDRESS: 39 PARK STREET
CITY, ST, ZIP: OMEGO NY 13827

PATIENT KEY: 22523121
PATIENT NAME: RATTIS MARIANNE
ADDRESS: 100 FRANKLIN ST
CITY, ST, ZIP: OMEGO NY 13827

TELEPHONE: 607-687-3273
BIRTHDATE: 07/05/1919

EX NUMBER	REFL NDC NUMBER	DRUG DESCRIPTION	PRESCRIBER NAME	DATE FILLED	RPH INT	QUANT DISP	PRIMARY PAYER #	SCDRY PAYER #	TOTAL PRICE	PRIMARY PD AMT	SCDRY PD AMT	PATIENT PD AMT
110518	3	00066985030 NORITATE 1% CREAM	FEDELE, CHARL R	06/10/1999	PC	30	7434		33.44	28.44	.00	5.00
112455	0	00071006720 ONITCEF 300MG CAPSULE	METCALFE, ANTHO	02/02/1999	LG	20	7300		60.96	60.96	.00	5.00
120709	0	01672123006 HYDROCORTISONE 0.2% CREAM	CHOI, SUSAN	09/20/1999	KA	45	7434		27.23	27.23	.00	.00
121662	0	0009454102 DETROL 1MG TABLET	CHOI, SUSAN	10/13/1999	LG	60	7434		68.52	63.52	.00	5.00
121689	0	00075150616 NASACORT AQ NASAL SPRAY	CHOI, SUSAN	10/13/1999	LG	17	7434		38.90	33.90	.00	5.00
121699	1	00075150616 NASACORT AQ NASAL SPRAY	CHOI, SUSAN	12/10/1999	LG	17	7434		38.90	33.90	.00	5.00
122359	0	00066985030 NORITATE 1% CREAM	FEDELE, CHARL R	10/29/1999	LG	30	7434		35.90	30.90	.00	5.00
122359	1	00066985030 NORITATE 1% CREAM	FEDELE, CHARL R	12/10/1999	LG	30	7434		35.90	30.90	.00	5.00
122360	0	00168008031 HYDROCORTISONE 2.5% CREAM	FEDELE, CHARL R	10/29/1999	LG	30	7434		35.90	30.90	.00	5.00
122398	0	00025152531 CEFEBREX 200MG CAPSULE	OVEN, THOMA J	11/13/1999	LG	30	7434		65.91	7.01	.00	.00
122498	1	00025152531 CEFEBREX 200MG CAPSULE	OVEN, THOMA J	12/07/1999	LG	30	7434		65.91	60.91	.00	5.00
124888	1	00006092531 FOSAMAX 5MG TABLET	OVEN, THOMA J	12/28/1999	LG	30	7434		55.72	50.72	.00	5.00
124888	2	00006092531 FOSAMAX 5MG TABLET	OVEN, THOMA J	02/07/2000	PC	30	7434		55.72	50.72	.00	5.00
124888	3	00006092531 FOSAMAX 5MG TABLET	OVEN, THOMA J	03/07/2000	LG	30	7434		55.72	50.72	.00	5.00
124888	4	00006092531 FOSAMAX 5MG TABLET	OVEN, THOMA J	06/05/2000	LG	30	7434		55.72	50.72	.00	5.00
124888	5	00006092531 FOSAMAX 5MG TABLET	OVEN, THOMA J	08/09/2000	PC	30	7434		55.72	50.72	.00	5.00
126094	0	00025152531 CEFEBREX 200MG CAPSULE	OVEN, THOMA J	01/21/2000	LG	30	7434		65.91	60.91	.00	5.00
126094	2	00025152531 CEFEBREX 200MG CAPSULE	OVEN, THOMA J	02/29/2000	PC	30	7434		65.91	60.91	.00	5.00
130413	0	00025152531 CEFEBREX 200MG CAPSULE	OVEN, THOMA J	04/01/2000	LG	30	7434		65.91	60.91	.00	5.00
130413	1	00025152531 CEFEBREX 200MG CAPSULE	OVEN, THOMA J	04/24/2000	LG	30	7434		65.91	60.91	.00	5.00
130413	2	00025152531 CEFEBREX 200MG CAPSULE	OVEN, THOMA J	06/05/2000	LG	30	7434		65.91	60.91	.00	5.00
135554	0	59762332701 METHYLPREDNISOLONE 4MG DS	CHOI, SUSAN	07/12/2000	PC	30	7434		12.07	10.07	.00	5.00
135555	0	00168008031 HYDROCORTISONE 2.5% CREAM	CHOI, SUSAN	08/21/2000	PC	21	7434		7.01	5.01	.00	2.00
135677	0	0034049401 HYDROXYZINE HCL 10MG TABL	CHOI, SUSAN	08/23/2000	PC	40	7434		13.49	11.49	.00	2.00
139194	0	0006092531 FOSAMAX 5MG TABLET	WHITLOCK, RPA-C	11/05/2000	PC	30	7434		60.30	55.30	.00	5.00
139290	0	0006092531 FOSAMAX 5MG TABLET	WHITLOCK, RPA-C	11/07/2000	PC	30	7434		60.30	55.30	.00	5.00
141055	0	0006092531 FOSAMAX 5MG TABLET	WHITLOCK, RPA-C	12/09/2000	LG	30	7434		60.30	55.30	.00	5.00
142436	0	00093117310 PENICILLIN VK 500MG TABLET	LALOR, ROBERT T	01/04/2001	PC	28	7434		4.81	2.81	.00	2.00
143978	0	0006011068 VIOXX 25MG TABLET	CHOI, SUSAN	01/30/2001	PC	15	7434		36.98	34.48	.00	2.50
143979	0	0006011068 VIOXX 25MG TABLET	CHOI, SUSAN	01/30/2001	PC	14	7434		22.72	17.72	.00	5.00
144919	0	00071053023 ACCURIL 10MG TABLET	CHOI, SUSAN	02/14/2001	LG	30	7434		30.13	25.13	.00	5.00
144919	1	00071053023 ACCURIL 10MG TABLET	CHOI, SUSAN	03/01/2001	PC	30	7434		30.13	25.13	.00	5.00
145752	0	00071053023 ACCURIL 10MG TABLET	CHOI, SUSAN	03/09/2001	PC	30	7434		30.13	25.13	.00	5.00
146173	1	0006011068 VIOXX 25MG TABLET	OVEN, THOMA J	04/11/2001	LG	30	7434		71.22	66.22	.00	5.00
146173	2	0006011068 VIOXX 25MG TABLET	OVEN, THOMA J	05/23/2001	LG	30	7434		71.22	66.22	.00	5.00
146173	3	0006011068 VIOXX 25MG TABLET	OVEN, THOMA J	06/28/2001	LG	30	7434		71.22	66.22	.00	5.00
146173	4	0006011068 VIOXX 25MG TABLET	OVEN, THOMA J	07/18/2001	LG	30	7434		71.22	65.22	.00	6.00

PAGE: 3 of 6
 RUN DATE: 12/17/2004
 REQUEST NBR: 1130937

CVS PHARMACY
 Patient Prescription Record
 01/01/1998 THRU 12/15/2004
 PHARMACY # 2252

PHARMACY NAME: CVS PHARMACY #2252
 ADDRESS: 39 PARK STREET
 CITY, ST, ZIP: OREGO NY 13827

TELEPHONE: 607-687-3273
 BIRTHDATE: 07/05/1919

PATIENT KEY: 22523121
 PATIENT NAME: RAFTIS MARIANNE
 ADDRESS: 100 FRANKLIN ST
 CITY, ST, ZIP: OREGO NY 13827

BX	REL	NUM	NUMBER	DRUG DESCRIPTION	PRESCRIBER NAME	DATE FILLED	REH INT	QUANT DISP	PRIMARY PAYER #	SCDRY PAYER #	TOTAL PRICE	PRIMARY PD AMT	SCDRY PD AMT	PATIENT PD AMT
146173	5	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	08/29/2001	LG	30	7434	7434		71.22	65.22	.00	6.00
148636	0	00006007744	FOSAMAX 35MG TABLET	OVEN, THOMA J	04/23/2001	LG	4	7434	7434		56.46	51.46	.00	5.00
148636	1	00006007744	FOSAMAX 35MG TABLET	OVEN, THOMA J	06/05/2001	PC	4	7434	7434		56.46	51.46	.00	5.00
148636	2	00006007744	FOSAMAX 35MG TABLET	OVEN, THOMA J	07/19/2001	LG	4	7434	7434		59.09	53.09	.00	6.00
148636	3	00006007744	FOSAMAX 35MG TABLET	OVEN, THOMA J	08/20/2001	KK	4	7434	7434		59.09	53.09	.00	6.00
148636	4	00006007744	FOSAMAX 35MG TABLET	OVEN, THOMA J	09/14/2001	LG	4	7434	7434		59.09	53.09	.00	6.00
148636	5	00006007744	FOSAMAX 35MG TABLET	OVEN, THOMA J	10/22/2001	LG	4	7434	7434		59.09	53.09	.00	6.00
152148	0	00071053023	ACCURIL 10MG TABLET	CHOI, SUSAN	06/28/2001	LG	60	7434	7434		57.52	52.52	.00	5.00
152286	0	51672129001	HYDROCHLORISONE 0.2% CREAM	CHOI, SUSAN	09/04/2001	KK	45	7434	7434		36.48	36.48	.00	.00
156771	0	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	10/01/2001	PC	30	7434	7434		74.58	68.58	.00	6.00
156771	1	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	11/02/2001	LG	30	7434	7434		74.58	68.58	.00	6.00
156771	2	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	12/04/2001	MB	30	7434	7434		74.58	68.58	.00	6.00
156771	3	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	01/07/2002	LL	30	7434	7434		74.58	68.58	.00	6.00
156771	4	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	02/04/2002	PC	30	7434	7434		74.58	68.58	.00	6.00
156771	5	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	02/25/2002	LG	30	7434	7434		74.58	68.58	.00	6.00
159752	1	00006007744	FOSAMAX 35MG TABLET	OVEN, THOMA J	11/20/2001	KK	4	7434	7434		59.09	53.09	.00	6.00
159752	2	00006007744	FOSAMAX 35MG TABLET	OVEN, THOMA J	01/09/2002	DP	4	7434	7434		59.09	53.09	.00	6.00
165578	0	00006007744	FOSAMAX 35MG TABLET	OVEN, THOMA J	03/12/2002	PC	4	7434	7434		59.09	53.09	.00	5.00
165578	1	00006007744	FOSAMAX 35MG TABLET	OVEN, THOMA J	04/09/2002	PC	4	7434	7434		59.09	53.09	.00	6.00
165578	2	00006007744	FOSAMAX 35MG TABLET	OVEN, THOMA J	04/26/2002	LG	4	7434	7434		62.41	56.41	.00	6.00
165578	3	00006007744	FOSAMAX 35MG TABLET	OVEN, THOMA J	06/08/2002	LG	4	7434	7434		62.41	56.41	.00	6.00
165578	4	00006007744	FOSAMAX 35MG TABLET	OVEN, THOMA J	07/01/2002	LG	4	7434	7434		60.54	53.54	.00	7.00
165578	5	00006007744	FOSAMAX 35MG TABLET	OVEN, THOMA J	08/13/2002	PC	4	7434	7434		60.54	53.54	.00	7.00
169162	0	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	04/09/2002	PC	30	7434	7434		74.58	68.58	.00	6.00
169162	1	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	05/29/2002	PC	30	7434	7434		74.58	68.58	.00	6.00
169162	2	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	08/03/2002	LG	30	7434	7434		72.43	65.43	.00	7.00
169162	3	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	09/08/2002	PC	30	7434	7434		72.43	65.43	.00	7.00
169162	4	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	09/30/2002	PC	30	7434	7434		72.43	65.43	.00	7.00
169162	5	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	11/04/2002	LG	30	7434	7434		76.08	69.08	.00	7.00
169162	6	00075150616	NASOCORT AQ NASAL SPRAY	CHOI, SUSAN	04/09/2002	PC	17	7434	7434		52.05	46.05	.00	6.00
174025	0	00093226401	AMOXICILLIN 875MG TABLET	CHAMBERLAIN, PATRI	07/23/2002	LG	14	7434	7434		12.44	12.44	.00	.00
177752	1	00006003144	FOSAMAX 70MG TABLET	OVEN, THOMA J	09/30/2002	PC	4	7434	7434		60.54	53.54	.00	7.00
177752	2	00006003144	FOSAMAX 70MG TABLET	OVEN, THOMA J	11/15/2002	PC	4	7434	7434		61.04	54.04	.00	7.00
177752	3	00006003144	FOSAMAX 70MG TABLET	OVEN, THOMA J	12/11/2002	AM	4	7434	7434		61.04	54.04	.00	7.00
177752	4	00006003144	FOSAMAX 70MG TABLET	OVEN, THOMA J	01/13/2003	LG	4	7434	7434		61.04	54.04	.00	7.00
177752	5	00006003144	FOSAMAX 70MG TABLET	OVEN, THOMA J	03/13/2003	PC	4	7434	7434		61.04	54.04	.00	7.00
181819	0	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	12/04/2002	LG	30	7434	7434		76.08	69.08	.00	7.00
181819	1	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	01/01/2003	LG	30	7434	7434		76.08	69.08	.00	7.00
181819	2	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	02/05/2003	PC	30	7434	7434		76.08	69.08	.00	7.00
181819	3	00006011068	VI0XX 25MG TABLET	OVEN, THOMA J	03/13/2003	PC	30	7434	7434		76.08	69.08	.00	7.00

CVS PHARMACY
Patient Prescription Record
01/01/1998 THRU 12/15/2004
PHARMACY # 2252

PAGE: 4 of 6
RUN DATE: 12/17/2004
REQUEST NBR: 1130937

PHARMACY NAME:
ADDRESS:
CITY, ST, ZIP:

CVS PHARMACY #2252
39 PARK STREET
OWEGO NY 13827

PATIENT KEY:

PATIENT NAME:
ADDRESS:
CITY, ST, ZIP:

22523121
RAFTIS MARIANNE
100 FRANKLIN ST
OWEGO NY 13827

TELEPHONE:
BIRTHDATE:

607-687-3273
07/05/1919

RX NUMBER	REF N/C	NUMBER	DRUG DESCRIPTION	PRESCRIBER NAME	DATE FILLED	RPH INT	QUANT DISP.	PRIMARY PAYER #	SCDRY PAYER #	TOTAL PRICE	PRIMARY PD AMT	SCDRY PD AMT	PATIENT PD AMT
188189	1	00006011063	VIOXX 25MG TABLET	OVEN, THOMA J	04/22/2003	PC	30	7434		76.08	69.08	.00	7.00
188189	2	00006011063	VIOXX 25MG TABLET	OVEN, THOMA J	07/07/2003	PG	30	7434		79.60	71.60	.00	8.00
188189	3	00006011063	VIOXX 25MG TABLET	OVEN, THOMA J	08/28/2003	LG	30	7434		79.60	71.60	.00	8.00
188189	4	00006011066	VIOXX 25MG TABLET	OVEN, THOMA J	11/25/2003	LG	30	7434		79.60	71.60	.00	8.00
190510	0	00006003144	FOSMAX 70MG TABLET	OVEN, THOMA J	04/22/2003	PC	12	7434		186.04	179.04	.00	7.00
194594	0	00006003144	FOSMAX 70MG TABLET	OVEN, THOMA J	08/20/2003	PC	12	7434		186.04	178.04	.00	8.00
194594	0	00378161001	DICYCLOMINE 10MG CAPSULE	SCOFELLITI, JOSEF	06/27/2003	PC	60	7434		9.92	9.92	.00	.00
194594	1	00378161001	DICYCLOMINE 10MG CAPSULE	SCOFELLITI, JOSEF	09/08/2003	LG	60	7434		9.92	9.92	.00	.00
194594	2	00378161001	DICYCLOMINE 10MG CAPSULE	SCOFELLITI, JOSEF	10/14/2003	LG	60	7434		9.92	9.92	.00	.00
194594	3	00378161001	DICYCLOMINE 10MG CAPSULE	SCOFELLITI, JOSEF	12/04/2003	PC	60	7434		9.92	9.92	.00	.00
197497	0	00378021801	ATENOLOL 25MG TABLET	TRAVERSE, PAUL W	08/15/2003	LG	30	7434		4.63	4.63	.00	.00
197497	1	00378021801	ATENOLOL 25MG TABLET	TRAVERSE, PAUL W	09/08/2003	LG	30	7434		4.63	4.63	.00	.00
197497	2	00378021801	ATENOLOL 25MG TABLET	TRAVERSE, PAUL W	10/14/2003	LG	30	7434		4.63	4.63	.00	.00
197497	3	00378021801	ATENOLOL 25MG TABLET	TRAVERSE, PAUL W	11/10/2003	PC	30	7434		4.63	4.63	.00	.00
197498	1	61570011201	ALTACE 5MG CAPSULE	TRAVERSE, PAUL W	09/15/2003	LG	30	7434		39.92	31.92	.00	8.00
197498	2	61570011201	ALTACE 5MG CAPSULE	TRAVERSE, PAUL W	09/08/2003	LG	30	7434		39.92	31.92	.00	8.00
197498	3	61570011201	ALTACE 5MG CAPSULE	TRAVERSE, PAUL W	10/14/2003	LG	30	7434		39.92	31.92	.00	8.00
197498	4	61570011201	ALTACE 5MG CAPSULE	TRAVERSE, PAUL W	11/10/2003	PC	30	7434		39.92	31.92	.00	8.00
197498	5	61570011201	ALTACE 5MG CAPSULE	TRAVERSE, PAUL W	12/16/2003	IS	30	7434		42.15	34.15	.00	8.00
197499	0	00006073531	ZOCOR 10MG TABLET	TRAVERSE, PAUL W	01/15/2004	PC	30	7434		69.77	61.77	.00	8.00
197499	1	00006073531	ZOCOR 10MG TABLET	TRAVERSE, PAUL W	08/15/2003	LG	30	7434		69.77	61.77	.00	8.00
197499	2	00006073531	ZOCOR 10MG TABLET	TRAVERSE, PAUL W	09/09/2003	LG	30	7434		69.77	61.77	.00	8.00
197499	3	00006073531	ZOCOR 10MG TABLET	TRAVERSE, PAUL W	10/14/2003	LG	30	7434		69.77	61.77	.00	8.00
197499	4	00006073531	ZOCOR 10MG TABLET	TRAVERSE, PAUL W	11/10/2003	PC	30	7434		69.77	61.77	.00	8.00
197499	5	00006073531	ZOCOR 10MG TABLET	TRAVERSE, PAUL W	12/16/2003	IS	30	7434		69.77	61.77	.00	8.00
198418	0	00378020801	FUROSEMIDE 20MG TABLET	SCHEIDER, ERICH	09/17/2003	PC	60	7434		5.30	5.30	.00	.00
198418	1	00378020801	FUROSEMIDE 20MG TABLET	SCHEIDER, ERICH	10/14/2003	LG	60	7434		5.30	5.30	.00	.00
201439	0	00378162001	DICYCLOMINE 10MG CAPSULE	SCHEIDER, ERICH	10/17/2003	EL	60	7434		10.10	10.10	.00	.00
202955	0	00006003144	FOSMAX 70MG TABLET	SCHEIDER, ERICH	12/01/2003	EL	21	7434		57.06	57.06	.00	.00
204316	0	00173056502	VALTREL 1GM CAPLET	CHOI, SUSAN J	02/11/2004	LG	12	7434		133.52	133.52	.00	8.00
205782	0	00006003144	FOSMAX 70MG TABLET	CHOI, SUSAN J	03/15/2004	PC	30	7434		181.69	181.69	.00	8.00
209210	1	61570011201	ALTACE 5MG CAPSULE	SCHEIDER, ERICH	04/14/2004	PC	30	7434		42.15	34.15	.00	8.00
209210	2	61570011201	ALTACE 5MG CAPSULE	SCHEIDER, ERICH	05/11/2004	PC	30	7434		42.15	34.15	.00	8.00
209210	3	61570011201	ALTACE 5MG CAPSULE	SCHEIDER, ERICH	06/12/2004	TA	30	7434		42.15	34.15	.00	8.00
209210	4	61570011201	ALTACE 5MG CAPSULE	SCHEIDER, ERICH	07/08/2004	LG	30	7434		42.15	34.15	.00	8.00
211149	0	00006003144	FOSMAX 70MG TABLET	SCHEIDER, ERICH	03/10/2004	LG	30	7434		5.99	5.99	.00	10.00
211483	0	00006003144	FOSMAX 70MG TABLET	SCHEIDER, ERICH	03/15/2004	PC	12	7434		181.69	181.69	.00	8.00
211483	1	00006003144	FOSMAX 70MG TABLET	SCHEIDER, ERICH	10/23/2004	LG	12	7434		181.69	181.69	.00	8.00
211483	2	00006003144	FOSMAX 70MG TABLET	SCHEIDER, ERICH						181.69	181.69	.00	8.00

CVS - 07309-02489004.0016 CVS# 077481 0000113037

CERTIFICATE OF SERVICE

I hereby certify that on this 24th day of April, 2008, I caused a copy of the foregoing DEFENDANT'S COMBINED REPLY MEMORANDUM IN SUPPORT OF MOTION TO STAY, AND IN OPPOSITION TO PLAINTIFF'S MOTION TO REMAND to be served via first-class mail, postage prepaid, on the following:


Ronald R. Benjamin, Esq.
LAW OFFICES OF RONALD R. BENJAMIN
126 Riverside Drive, P.O. Box 607
Binghamton, New York 13902

The above address has appeared on the prior papers in this action as the office address of the attorneys for Plaintiff.

Deponent is over the age of 18 years and not a party to this action.

I further certify under penalty of perjury that under the laws of the United States of America the foregoing is true and correct.

Executed on April 24, 2008


Jennifer Alpern Hecht